

Subject Index

A

ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)

cyclic delivery of MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) and, in stage IV Hodgkin's disease, 881

Acivicin

plasma and cerebrospinal fluid pharmacokinetics of, in Om-maya reservoir-bearing rhesus monkeys, 1333

Aclacinomycin A

flare (skin reaction), 1683

a phase I trial of, 1127

ACNU (1-(aminomethyl)-3-(2-chloroethyl)-3-nitrosourea)

with 5-FU and mitomycin (FUM) for carcinoma of the pancreas, 1645

Actinomycin D *see* Dactinomycin

Adenosine

comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs and tubercidin and, alone or combined with 2'-deoxycoformycin, 317

Adriamycin *see* Doxorubicin

Adverse effects, animals

cardiac and renal toxicity of daunorubicin compared in the rat and rabbit, 395

cisplatin-induced emesis in the ferret: a new animal model, 187

cyclophosphamide-induced cardiomyopathy in the rat, 1521

ganglioneuropathy in rabbits and rhesus monkey due to high cumulative doses of doxorubicin, 1349

malnutrition effect on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat, 85

noninvasive documentation of emesis in cats, 362

prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO), 1371

toxicity of aziridinybenzoquinone administered iv to beagle dogs, 1845

toxicity (local and systemic) resulting from large-volume ip administration in the rat, 157

vomiting induced by cyclophosphamide and phosphoramide mustard in cats, 1625

Adverse effects, man

aclacinomycin A flare (skin reaction), 1683

acute ECG changes associated with AMSA treatment, 1678

acute leukemia after semustine (methyl-CCNU) therapy: a case report, 1593

acute vascular episodes associated with therapy for carcinomas of the upper aerodigestive tract with bleomycin, vincristine, and cisplatin, 369

allergic reaction following administration of AMSA, 594

aminoglutethimide-induced thrombocytopenia, 1785

antidiuretic hormone (ADH) elevation with chemotherapy-induced emesis, 25

anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, 1601

apparent cyclophosphamide sensitivity: urticaria associated with cyclophosphamide without prior sensitization, 2106

cardiac abnormalities after AMSA administration, 483

combination antiemetics, 1449

the course of nausea and vomiting after high-dose cyclophosphamide, 1487

effective control of cisplatin-induced nausea using high-dose steroids and droperidol, 243

enhanced bleomycin toxicity during acute renal failure, 592

epileptic seizures associated with cisplatin administration, 1719

fatal hepatotoxicity associated with AMSA therapy, 1863

fever due to 6-mercaptopurine, 1785

hemolytic-uremic syndrome associated with mitomycin therapy, 457

inadvertent overdose with lomustine (CCNU) followed by hematologic recovery, 1241

leukopenia associated with aminoglutethimide therapy: a case report, 1879

leukemia occurring after treatment of small cell lung cancer, 1683

mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature, 1244

nasal cartilage necrosis following high-dose 5-FU: a case report, 1884

neurologic and cardiac toxicity following iv application of methotrexate, 1561

ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration, 19

persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer, 1767

potential cardiotoxicity with mitoxantrone, 1641

pulmonary fibrosis associated with lomustine (CCNU): a case report, 1881

reactions to AMSA in medical personnel, 1885

severe toxicity and death associated with zidovudine administration, 410

streptozocin-induced eosinophilia and fever: a case report, 1449

subcutaneous reaction due to intra-arterial infusion of doxorubicin, 2000

unusual reaction to VP-16-213 and avoidance by prolonged infusion, 409

vindesine-associated angina and ECG changes, 587

vindesine overdose, 1247

L-Alanosine

using a daily \times 3 schedule: a phase I study, 73

Alkeran *see* Melfalan

Allopurinol

cerebrospinal fluid versus serum concentrations of 5-FU, oxypurinol and, during treatment of metastatic brain can-

cer with 5-FU infusion, allopurinol, and radiation, 571
combined with 5-FU and hypoxanthine in chemotherapy for
human colon adenocarcinoma xenografts, 1201
and 5-FU: toxicity modulation and phase II results in colon
cancer, 1133
modulation of 5-FU toxicity with high dose of: phase I trial
of an outpatient dose schedule, 1723

Aminoglutethimide

leukopenia associated with therapy, 1879
thrombocytopenia induced by, 1785

AMSA

acute ECG changes associated with treatment, 1678
adverse reactions to, in medical personnel, 1885
allergic reaction following administration of, 594
autologous bone marrow transplantation and high-dose, in
relapsed acute leukemia, 1991
cardiac abnormalities after administration of, 483
evaluation in patients with stage III-IV malignant mel-
anoma: a phase II study, 1237
fatal hepatotoxicity associated with therapy, 1863
high-dose, and bone marrow rescue in patients with solid
tumors, 385
in patients with advanced ovarian cancer: a phase II study,
1242
in patients with metastatic breast cancer: a Cancer and Leu-
kemia Group B phase II study, 1211
with prednisone and chlorambucil (APC) in the treatment
of refractory breast cancer: a Northern California Oncol-
ogy Group study, 1235
in previously treated patients with stage III and IV ovarian
cancer: a phase II study, 1589
in prostatic cancer: a phase II study, 208
promising new agent in refractory acute leukemia, 1475
therapy for children with lymphoblastic malignancy, 593
trial of, in acute leukemia, 1596
in vitro evaluation of the cardiotoxic potential of, 1571

m-AMSA

administered as a continuous infusion: a phase I-II study,
1813
in disseminated prostatic carcinoma: a phase II study, 1993
in hepatocellular carcinoma: a Southwest Oncology Group
phase II study, 1651

Anal cancer *see* Cancer, anal

Anguidine

in gastrointestinal malignancies: a Southwest Oncology Group
phase II study, 381

Anthracenedione

response of transplantable tumors of mice to derivatives
alone and in combination with clinically useful agents, 1187

Anthracyclines

lack of correlation between effects of, on in vitro cardiac
guanyl cyclase and in vivo cardiotoxicity, 1677

Antidiuretic hormone (ADH)

elevation associated with chemotherapy-induced emesis in
man, 25

Antineoplastic drugs

absorption following large-volume ip administration to rats,
147

9- β -D-Arabinofuranosyladenine (Ara-A)

and 2'-deoxycytosine (DCF) in the treatment of refrac-
tory acute myelocytic leukemia, 253

Ara-C *see* Cytarabine

Aryldimethyltriazenes

metabolism and mechanism of the antileukemic action of is-
omeric, 1751

prophylactic antimetastatic treatment as adjuvants to sur-
gical tumor removal in mice bearing Lewis lung carci-
noma, 115

L-Asparaginase

randomized phase II comparison of methotrexate with or
without, in non-small cell cancer of the lung, 541

5-Azacitidine

treatment of the blast crisis of chronic myelogenous leuke-
mia with VP-16-213 (etoposide) and, 267
and zorubicin for patients with previously treated acute non-
lymphocytic leukemia: a Cancer and Leukemia Group B
pilot study, 563

Azapicyl

evaluation in soft tissue sarcomas in children: a report from
the Children's Cancer Study Group, 399

Aziridinybenzoquinone (AZQ)

in advanced breast cancer: a Cancer and Leukemia Group
B phase II trial, 1875
biochemical activation to its free radical species, 339
clinical and pharmacologic studies of, 1321
in disseminated malignant melanoma: a phase II study, 2089
in head and neck cancer: a phase II trial, 2097
toxicity of, administered iv to beagle dogs, 1845
in the treatment of central nervous system leukemia, 2105

AZQ *see* Aziridinybenzoquinone

B

Baker's antifol

studies of methotrexate, razoxane, and, in advanced gastric
cancer: a Gastrointestinal Tumor Study Group report, 1713

BCNU *see* Carmustine

Benzohydroxamic acids

cytotoxic and cell kinetic effects of 3,4,5-trihydroxybenzo-
hydroxamic acid, 2071
modulation of cytarabine metabolism in the human promye-
locytic leukemia cell line HL-60 by polyhydroxy-substi-
tuted, 1825

Bisantrone

in advanced colorectal cancer: a Cancer and Leukemia Group
B phase II study, 1997
for advanced hypernephroma: a phase II trial, 1653
disposition and metabolic profile of a new antitumor agent
in laboratory animals, 1173
in patients with renal cell carcinoma: a phase II evaluation,
1869
a phase I clinical evaluation of, 1517

Bleomycin

acute vascular episodes associated with therapy for carci-
nomas of the upper aerodigestive tract with vincristine,
cisplatin, and, 369
with cisplatin, vincristine, and methotrexate in advanced
non-small cell bronchogenic carcinoma, 205
combined chemotherapy with doxorubicin, vinblastine, and
dacarbazine, and radiotherapy for advanced lymphoepi-
thelioma, 1207

combination with vinblastine and cisplatin in advanced malignant melanoma: a phase II study, 567
 coronary artery disease in presence of therapy with, 410
 with cyclophosphamide, doxorubicin, vincristine, and prednisone, compared with doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine in the treatment of diffuse histiocytic lymphoma, 1279
 enhanced toxicity of, during acute renal failure, 592
 and hydroxyurea combination chemotherapy in the treatment of advanced head and neck cancer, 1439
 intracavitary, in the management of malignant effusions: a multicenter study, 1903
 with mitomycin, sequential combination in advanced cervical cancer: a Northern California Oncology Group study, 163
 potentiation of toxicity by oxygen, 359
 serial analysis of melanoma growth kinetics in a patient receiving procarbazine and: comparison of tumor volume, flow cytometry, and thymidine labeling techniques, 529
 with vincristine and carmustine (BCNU) in patients with squamous cell bronchial carcinoma resistant to cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP), 1877
 with vinblastine and cisplatin, treatment of advanced malignant melanoma with, 1299

Brain cancer *see* Cancer, brain

Breast cancer *see* Cancer, breast

Bronchial cancer *see* Cancer, bronchial

Bronchogenic cancer *see* Cancer, bronchogenic

Butorphanol

antiemetic activity against cisplatin-induced emesis in ferrets and dogs, 1831

C

CAM (cyclophosphamide, doxorubicin, and methotrexate)
 random prospective study of combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer, 2005

CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
 combination chemotherapy with vincristine, carmustine (BCNU), and bleomycin in patients with squamous cell bronchial carcinoma resistant to, 1877

Cancer

advanced

indicine-*N*-oxide in patients with: a phase I study, 1509
 pilot study of PALA (*N*-phosphonoacetyl-L-aspartate) and 5-FU in patients with, 77

anal

combined radical radiation therapy and chemotherapy for primary squamous cell carcinoma, 489

bone

chemotherapy for osteogenic sarcoma: an investigative method, not a recipe, 1687

ethics of not conducting a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma, 1699

primary non-Hodgkin's lymphoma of: results in 15 patients treated by radiotherapy combined with systemic chemotherapy, 1859

and soft tissue sarcomas, gallium nitrate in advanced: a Southwest Oncology Group study, 1673

brain

carmustine (BCNU) and dianhydrogalactitol combination in the treatment of primary, recurring after irradiation, 1647

cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic, with 5-FU infusion, allopurinol, and radiation, 571

cisplatin therapy in recurrent childhood tumors, 2013

platinum concentrations in human glioblastoma multiforme following the use of cisplatin, 1661

proper analysis of clinical trials for malignant glioma, 211
 breast

AMSA in patients with metastatic: a Cancer and Leukemia Group B phase II study, 1211

AMSA, prednisone, and chlorambucil (APC) in the treatment of refractory: a Northern California Oncology Group study, 1235

AMSA in refractory: phase II study, 403

anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU adjuvant chemotherapy for carcinoma, 1601

aziridinylbenzoquinone (AZQ) in advanced: a Cancer and Leukemia Group B phase II trial, 1875

chlorozotocin in malignant melanoma, other solid tumors, and: a phase I trial, 1229

3-deazaguanine: a candidate drug for the chemotherapy of carcinomas? 1853

doxorubicin as a single agent in patients with previously untreated: experience of the Eastern Cooperative Oncology Group, 1594

hydroxy-9-methyl-2-ellipticinium for osseous metastases from: a 5-year experience, 1909

Estracyt in advanced, a pilot study, 581

failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory, 1783

gallium nitrate in: a Southwest Oncology Group phase II study, 1591

high-dose medroxyprogesterone acetate in advanced male, 1763

spirogermanium in adenocarcinoma: a Cancer and Leukemia Group B phase II study, 1667

tamoxifen before and after orchiectomy in advanced male, 1882

third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory carcinoma: a pilot study, 559

vincristine, doxorubicin, prednisolone, and cyclophosphamide (VAP-cyclo)—a short intensive regimen for advanced, 1999

vindesine in patients with advanced: a phase II study, 1729
 bronchogenic

bleomycin, cisplatin, vincristine, and methotrexate in advanced non-small cell carcinoma, 205

combination chemotherapy for, with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group, 199

divided-dose vinblastine in carcinoma: a phase II study, 171

- doxorubicin and mitomycin in non-small cell: a phase II study, 177
- upper hemibody and local chest irradiation as consolidation following response to high-dose induction chemotherapy for small cell carcinoma—a pilot study, 1609
- bronchial
- combination chemotherapy with vincristine, carmustine (BCNU), and bleomycin in patients with squamous cell carcinoma resistant to cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP), 1877
 - tumor size, response rate, and prognosis in small cell carcinoma treated by combination chemotherapy, 463
- carcinoma
- multiple squamous cell, treated with intra-arterial cisplatin in a patient with rheumatoid arthritis, 1987
- cervical
- dianhydrogalactitol and cisplatin in combination for advanced, 1809
 - sequential combination of bleomycin and mitomycin in advanced: a Northern California Oncology Group study, 163
- cholangiocarcinoma
- response to doxorubicin and mitomycin: a case report, 209
- colon
- 5-FU and allopurinol: toxicity modulation and phase II results in, 1133
 - methyl-GAG in advanced: a phase II trial of the Southwest Oncology Group, 2099
- colorectal
- bisantrene in advanced: a Cancer and Leukemia Group B phase II study, 1997
 - combination chemotherapy in patients with advanced, previously treated with 5-FU, 2093
 - 4'-epi-doxorubicin in patients with advanced carcinoma: a phase II evaluation, 1757
 - and gastric adenocarcinomas, advanced, treatment with 5-FU combined with high-dose folinic acid (leucovorin): a pilot study, 1803
 - high-dose intermittent cycloleucine in: a phase II study, 203
 - mitoxantrone in advanced: a phase II study, 1995
 - mitoxantrone in patients with previously untreated adenocarcinoma: a Southwest Oncology Group phase II trial, 1779
 - sequential methotrexate-5-FU therapy in advanced measurable, 1563
 - sequential methotrexate and 5-FU in the treatment of, 1553
 - vindesine for patients with advanced carcinoma: a phase II evaluation, 583
- endometrial
- etoposide in the management of advanced or recurrent carcinoma: a Gynecologic Oncology Group phase II trial, 1669
- esophageal
- methyl-GAG in the treatment of carcinoma: a phase II study, 1427
- gastrointestinal
- advanced colorectal and gastric adenocarcinomas, treatment with 5-FU combined with high-dose folinic acid (leucovorin): a pilot study, 1803
 - anguidine in: a Southwest Oncology Group phase II study, 381
 - 5-FU, doxorubicin, and mitomycin (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas: phase I-II study, 1613
 - randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric, 1263
 - studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: a Gastrointestinal Tumor Study Group report, 1713
- germ cell
- VAB-3 combination chemotherapy in mediastinal tumors, 1405
- head and neck
- aziridinylbenzoquinone (AZQ) in: phase II trial, 2097
 - bleomycin and hydroxyurea combination chemotherapy in the treatment of, 1439
 - clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma, 471
 - combination chemotherapy used prior to radiation therapy for locally advanced squamous cell carcinoma, 1421
 - methotrexate and 5-FU for recurrent, 1925
 - razoxane (ICRF-159) in patients with squamous cell carcinoma, previously exposed to systemic chemotherapy, 557
 - thioprolin in advanced epidermoid: a phase II trial, 585
- Hodgkin's disease *see* Hodgkin's disease
- hypernephroma
- bisantrene for advanced: a phase II trial, 1653
- Kaposi's sarcoma
- the epidemic of acquired immune dysfunction in homosexual men and its sequelae—opportunistic infections, Kaposi's sarcoma, and other malignancies: an update and interpretation, 1391
 - workshop on: meeting report, 1387
- liver
- m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group phase II trial, 1651
 - isotopic immunoglobulin therapy for primary: a phase I-II study, 289
- lung
- CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell carcinoma, 1557
 - chemotherapy versus chemimmunotherapy with levamisole or *Corynebacterium parvum* in advanced, 1291
 - cisplatin combination chemotherapy in non-oat cell carcinoma, 197
 - cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell, 247
 - cisplatin, maytansine, and chlorozotocin in small cell carcinoma: a phase II study, 1417
 - combination chemotherapy for small cell carcinoma: continuous versus alternating non-cross-resistant combinations, 221
 - deoxynorleucine (DON) in patients with previously treated advanced: a phase II study, 1665
 - extensive adenocarcinoma and large cell undifferentiated carcinoma treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group study, 553
 - high-dose cisplatin for, 375

- intensive timed sequential combination chemotherapy in extensive-stage small cell carcinoma, 1880
- lack of efficacy of high-dose methotrexate by 30-hour infusion in patients with progressive small cell carcinoma, 1223
- leukemia occurring after treatment of small cell, 1683
- limited squamous cell: a Southwest Oncology Group randomized study of radiation with or without doxorubicin chemotherapy and with or without levamisole immunotherapy, 1113
- mitomycin, hexamethylmelamine, and vindesine as second-line treatment for small cell, 1873
- non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma, 1399
- procarbazine in small cell carcinoma: a phase II study, 273
- random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non-small cell, 2005
- randomized phase II comparison of methotrexate with or without L-asparaginase in non-small cell, 541
- vindesine: an effective agent in the treatment of non-small cell, 1709
- vindesine monotherapy for non-small cell: a report of 45 cases, 1409
- vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of, 305
- lymphoepithelioma
- combined chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine, and radiotherapy for advanced, 1207
- lymphoma
- AMSA therapy for children with lymphoblastic malignancy, 593
- combination chemotherapy for patients with relapsed malignant, using methyl-GAG and teniposide (VM-26), 1121
- comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant, 2021
- comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse, 1279
- comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's, 43
- cyclophosphamide and prednisolone high-dose regimen in advanced non-Hodgkin's, of favorable histologic type: phase II study, 377
- deferral of initial therapy for advanced indolent, 417
- maytansine in refractory non-Hodgkin's: a Southwest Oncology Group phase II study, 1587
- methotrexate (COP or CHOP) combinations in the treatment of previously untreated and treated, 43
- prognostic significance of the Lukes and Collins classification in patients treated with COMLA (cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine), 1107
- role of combined modality therapy in the curative management of advanced-stage "favorable" non-Hodgkin's, 421
- salvage chemotherapy for non-Hodgkin's, 1977
- melanoma
- AMSA in patients with stage III-IV malignant, 1237
- an aziridinylbenzoquinone (AZQ) in disseminated malignant: a phase II study, 2089
- chlorozotocin in breast cancer, other solid tumors, and malignant: phase I trial, 1229
- chlorozotocin in malignant: a Southwest Cancer Study Group phase II study, 1431
- cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant: a Southwest Oncology Group study, 31
- clinical trial of chlorozotocin, DTIC, and dactinomycin in malignant, 371
- combination of vinblastine, bleomycin, and cisplatin in advanced malignant: a phase II study, 567
- high-dose megestrol acetate in patients with advanced malignant: a phase II study, 1239
- mitolactol in patients with metastatic: a phase II trial, 195
- mitolactol and semustine combination chemotherapy for advanced malignant, 1425
- serial analysis of growth kinetics in a patient receiving bleomycin and procarbazine therapy: comparison of tumor volume, flow cytometry, and thymidine labeling techniques, 529
- tamoxifen in malignant: a phase II study, 1447
- tamoxifen in metastatic, Southwest Oncology Group experience with, 1680
- tamoxifen in patients with metastatic malignant: a phase II study, 1437
- tamoxifen in the treatment of metastatic malignant, 1771
- therapeutic effect of dopamine infusion on human malignant, 1657
- treatment of advanced malignant, with vinblastine, bleomycin, and cisplatin, 1299
- mesothelioma
- doxorubicin and radiation therapy combination in malignant pleural, 1605
- mycosis fungoides
- combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP) in TNM-classified stage IV, 167
- myeloma
- combination chemotherapy for multiple, with melphalan, prednisone, cyclophosphamide, vincristine, and BCNU (M-2 protocol), 1971
- cisplatin, BCNU, cyclophosphamide, and prednisone in multiple, 237
- resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone, 451
- treatment of advanced plasma cell, with weekly cyclophosphamide and alternate-day prednisone, 1413
- vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple: a Southwest Oncology Group study, 1267
- ovarian
- AMSA in patients with advanced: a phase II study, 1242
- AMSA in previously treated patients with stage III and IV: a phase II study, 1589
- hexamethylmelamine-CAF (cyclophosphamide, metho-

- trexate, and 5-FU) and cisplatin-CAF in refractory, 1233
- hexamethylmelamine and cisplatin in, after failure of alkylating-agent therapy, 1285
- hexamethylmelamine distribution in patients with, and other pelvic cancers, 231
- high-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant carcinoma: a phase II study, 407
- high-dose medroxyprogesterone acetate for the treatment of advanced carcinoma, 1441
- ip immunotherapy and chemotherapy in advanced epithelial, 1977
- pharmacology and toxicity of ip streptozocin in: a case study, 1595
- spirogermanium in advanced epithelial carcinoma: a phase II study, 1675
- Yoshi 864 in epithelial carcinoma: a Gynecologic Oncology Group phase II clinical study, 1775
- pancreatic**
- combination chemotherapy with 5-FU and 1-(amino-methyl)-3-(2-chloroethyl)-3-nitrosourea for carcinoma, 1645
- doxorubicin therapy for advanced islet cell carcinoma: a phase II study, 1567
- 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measurable: a phase II study, 2095
- radiation therapy combined with intra-arterial 5-FU chemotherapy for treatment of localized adenocarcinoma: a Southwest Oncology Group study, 549
- prostatic**
- AMSA in: a phase II study, 208
- m-AMSA in disseminated carcinoma: a phase II study, 1993
- cisplatin, cyclophosphamide, and prednisone therapy for stage D, 1403
- cyclophosphamide, doxorubicin, and methotrexate in the treatment of advanced, 1797
- doxorubicin, mitomycin, and 5-FU in the treatment of hormone-resistant stage D: a preliminary report, 57
- renal cell**
- bisantrene in patients with carcinoma: a phase II evaluation, 1869
- dianhydrogalactitol in advanced carcinoma: a Southwest Oncology Group phase II study, 1231
- medroxyprogesterone acetate with tamoxifen in advanced, 1773
- soft tissue**
- and bone sarcomas, gallium nitrate in advanced: a Southwest Oncology Group study, 1673
- evaluation of azapiclyl in children with sarcoma: a report from the Children's Cancer Study Group, 399
- prednimustine in advanced sarcoma, 201
- T-cell**
- cytarabine in chronic neoplasms, 591
- effect of cytarabine on development of cytotoxic, 535
- testicular**
- clinical stage I: the medical oncologist's view, 15
- introduction to current controversies in management of, 1
- optimal management of clinical stage I nonseminomatous carcinoma: one oncologist's view, 11
- persistent hypomagnesemia following cisplatin chemotherapy for, 1767
- surgical treatment of clinical stage I nonseminomatous germ cell tumors, 5
- urinary tract**
- 4'-epi-doxorubicin in metastatic renal: a phase II study, 1219
- management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy, 1501
- methyl-GAG and vinblastine combination in the treatment of metastatic renal adenocarcinoma, 1585
- PALA in hypernephroma and urinary bladder cancer: a phase II trial, 2091
- VM-26 in patients with metastatic transitional cell carcinoma: an Eastern Cooperative Oncology Group phase II evaluation, 405
- Yoshi 864 plus medroxyprogesterone in adenocarcinoma of the kidney: a Southwest Oncology Group study, 1781
- Wilms' tumor**
- invited comment on the Milwaukee pilot study of doxorubicin-vincristine therapy for, 1795
- vincristine-doxorubicin therapy for: a pilot study, 1791
- Carmustine (BCNU)**
- with cisplatin, cyclophosphamide, and prednisone in multiple myeloma, 237
- with cyclophosphamide and doxorubicin, combination chemotherapy for bronchogenic carcinoma: a pilot study of the Southeastern Cancer Study Group, 199
- and dianhydrogalactitol combination in the treatment of primary brain tumors recurring after irradiation, 1647
- with doxorubicin, cyclophosphamide, and prednisone in the treatment of multiple myeloma resistant to melphalan, 451
- intermittent with cyclophosphamide and prednisone versus intermittent melphalan and prednisone in myeloma, 1273
- with melphalan, prednisone, cyclophosphamide, and vincristine (M-2 protocol): combination chemotherapy for multiple myeloma, 1971
- with mitomycin and vinblastine as third-line chemotherapy in refractory breast carcinoma: a pilot study, 559
- with vincristine and bleomycin in patients with squamous cell bronchial carcinoma resistant to cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP), 1877
- vincristine, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 1267
- CCNU see lomustine**
- Cell culture studies**
- action of lycurim and pyrazofurin on hepatoma 3924A cells in culture, 343
- chemotherapy sensitivity assessment of leukemic colony-forming cells with in vitro simultaneous exposure to multiple drugs: clinical correlations in acute nonlymphocytic leukemia, 1257
- comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs and tubercidin and adenosine alone or in combination with 2'-deoxycytosine, 317
- comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines, 2051
- development and characterization of a cyclophosphamide-

- resistant mouse plasmacytoma cell line, 1535
- doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line, 121
- increased relative effectiveness of doxorubicin against slowly proliferating Sarcoma 180 cells after prolonged drug exposure, 1159
- modulation of cytarabine metabolism in the human promyelocytic leukemia cell line HL-60 by polyhydroxy-substituted benzohydroxamic acids, 1825
- Cervical cancer** *see* Cancer, cervical
- Chemoinmunotherapy**
- for autochthonous acute rat leukemias, 391
- Chemotherapy**
- changes in intestinal permeability to lactulose induced by cytotoxic, 1435
- versus chemoinmunotherapy with levamisole or *Corynebacterium parvum* in advanced lung cancer, 1291
- combination used prior to radiation therapy for locally advanced squamous cell carcinoma of the head and neck, 1421
- intensive timed sequential, in extensive-stage small cell carcinoma of the lung, 1880
- management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv, 1501
- Chlorambucil**
- with AMSA and prednisone (APC) in the treatment of refractory breast cancer: a Northern California Oncology Group study, 1235
- Chlorozotocin**
- with cisplatin and maytansine in small cell lung carcinoma (EST 2578): a phase II study, 1417
- with DTIC and dactinomycin, clinical trial in metastatic malignant melanoma, 371
- in malignant melanoma, breast cancer, and other solid tumors: phase I trial, 1229
- in malignant melanoma: a Southeastern Cancer Study Group phase II study, 1431
- Cholangiocarcinoma** *see* Cancer, cholangiocarcinoma
- Cisplatin**
- acute vascular episodes associated with therapy for carcinomas of the upper aerodigestive tract with bleomycin, vincristine, and, 369
- antiemetic activity of butorphanol against emesis induced by, in ferrets and dogs, 1831
- antitumor activity and toxicity of analogs of, 135
- with BCNU, cyclophosphamide, and prednisone in multiple myeloma, 237
- with bleomycin, vincristine, and methotrexate in advanced non-small cell bronchogenic carcinoma, 205
- clinical trial of 5-FU infusion and, as initial treatment for advanced squamous cell carcinoma of the head and neck, 471
- combination chemotherapy in non-oat cell carcinoma of the lung, 197
- combination with vinblastine and bleomycin in advanced malignant melanoma: a phase II study, 567
- with cyclophosphamide, methotrexate, and 5-FU and hexamethylmelamine-CAF in refractory ovarian cancer, 1233
- with cyclophosphamide and prednisone, therapy for stage D prostatic cancer, 1403
- and dianhydrogalactitol in combination for advanced cancer of the uterine cervix, 1809
- with doxorubicin, cyclophosphamide, and vindesine, combination chemotherapy for non-small cell lung cancer, 247
- epileptic seizures associated with administration of, 1719
- experimental ultrastructural and X-ray microanalysis study of, in the rat: intracellular localization of platinum, 1529
- and hexamethylmelamine in advanced ovarian cancer after failure of alkylating-agent therapy, 1285
- high-dose for lung cancer, 375
- hydration with and without mannitol diuresis in refractory malignant melanoma: a Southwest Oncology Group study, 31
- induced emesis in the ferret: a new animal model, 187
- induced emesis, results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of, 1975
- induced nausea, effective control using high-dose steroids and droperidol, 243
- with maytansine and chlorozotocin in small cell lung carcinoma (EST 2578): a phase II study, 1417
- multiple squamous cell carcinoma treated with intra-arterial, in a patient with rheumatoid arthritis, 1987
- ototoxicity in patients receiving: importance of dose and method of drug administration, 19
- persistent hypomagnesemia following chemotherapy with, for testicular cancer, 1767
- platinum concentrations in human glioblastoma multiforme following the use of, 1661
- in recurrent childhood brain tumors, 2013
- urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism, 1933
- with vinblastine and bleomycin, treatment of advanced malignant melanoma with, 1299
- Clinical trials**
- chemotherapy for osteogenic sarcoma: an investigative method, not a recipe, 1687
- a data-based approach to assessing clinical interventions in the setting of chronic disease, 1077
- design of controlled clinical trials: use of historical controls, 1089
- editorial on management of drug toxicity, 1901
- ethics of not conducting a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma, 1699
- historical controls, data banks, and randomized trials in clinical research: a review, 1101
- nonparametric confidence limits for survival probabilities and median survival time, 37
- oral complications of cancer chemotherapy: present status and future studies, 1251
- proper analysis of clinical trials for malignant glioma, 211
- randomized clinical trials and research strategy, 1083
- rationale for the use of alternative non-cross-resistant chemotherapy, 439
- statistical guidelines for medical research reports, 217
- strategy and alternate randomized designs in cancer clinical trials, 1095
- Colon cancer** *see* Cancer, colon
- Colorectal cancer** *see* Cancer, colorectal
- COMLA (cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine)**
- prognostic significance of the Lukes and Collins classification in patients treated with, 1107

Corynebacterium parvum

or levamisole chemoimmunotherapy versus chemotherapy in advanced lung cancer, 1291

Cycloleucine

intermittent high-dose in colorectal malignancies: a phase II study, 203

Cyclophosphamide

anticipatory vomiting in women with breast carcinoma receiving adjuvant chemotherapy with methotrexate, 5-FU, and, 1601

apparent sensitivity to: urticaria associated with cyclophosphamide without prior sensitization, 2106

with BCNU and doxorubicin, combination chemotherapy for bronchogenic carcinoma: a pilot study of the Southeastern Cancer Study Group, 199

with cisplatin, BCNU, and prednisone in multiple myeloma, 237

with cisplatin, doxorubicin, and vindesine, combination chemotherapy for non-small cell lung cancer, 247

with cisplatin and prednisone, therapy for stage D prostatic cancer, 1403

the course of nausea and vomiting after high-dose, 1487

with doxorubicin, carmustine (BCNU), and prednisone in the treatment of multiple myeloma resistant to melphalan, 451

with doxorubicin and methotrexate (CAM), random prospective study of combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer, 2005

with doxorubicin and methotrexate in the treatment of advanced prostate cancer, 1797

with doxorubicin, vincristine, methotrexate with leucovorin rescue, and cytarabine, compared with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin in the treatment of diffuse histiocytic lymphoma, 1279

and fltorafur combination chemotherapy against advanced L1210 murine leukemia, 1631

with hexamethylmelamine, methotrexate, and 5-FU and cisplatin-CAF in refractory ovarian cancer, 1233

intermittent with carmustine (BCNU) and prednisone versus intermittent melphalan and prednisone in myeloma, 1273

-induced bladder toxicity, influence of diuretics on urinary general base catalytic activity and, 1889

with melphalan, prednisone, vincristine, and BCNU (M-2 protocol): combination chemotherapy for multiple myeloma, 1971

and prednisolone, high-dose regimen in advanced non-Hodgkin's lymphoma of favorable histologic type, 377

-resistant cell line, development and characterization of, 1535

transplacental passage of, 1681

with vincristine, doxorubicin, and prednisolone (VAP-Cyclo): a short intensive regimen for advanced breast cancer, 1999

with vincristine and prednisone (CVP), combination chemotherapy in TNM-classified stage IV mycosis fungoides, 167

vomiting induced by phosphoramide mustard and, in cats, 1625

weekly treatment of advanced plasma cell myeloma with, and alternate-day prednisone, 1413

Cytarabine

in chronic T-cell neoplasms, 591

with doxorubicin, cyclophosphamide, vincristine, and methotrexate with leucovorin rescue, compared with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin in the treatment of diffuse histiocytic lymphoma, 1279

effects compared with two nonclassic folic acid antagonists and methotrexate on hematopoietic precursor cells, 499

effect on cytotoxic T-cell development, 535

metabolism modulation in the human promyelocytic leukemia cell line HL-60 by polyhydroxy-substituted benzo-hydroxamic acids, 1825

with mitomycin and 5-FU, randomized comparison in the treatment of advanced gastric cancer, 1263

and pyrazofurin, treatment of refractory acute nonlymphocytic leukemia with a combination of, 1397

response of hyper eosinophilic syndrome to 6-thioguanine and, 545

Cytosine arabinoside *see* Cytarabine

Cytosan *see* Cyclophosphamide

D

Dacarbazine (DTIC)

with chlorozotocin and dactinomycin, clinical trial in metastatic malignant melanoma, 371

combined chemotherapy with doxorubicin, bleomycin, and vinblastine, and radiotherapy for advanced lymphoepithelioma, 1207

control of emesis induced by, with high-dose metoclopramide in a preliminary trial, 2108

Dactinomycin

with chlorozotocin and DTIC, clinical trial in metastatic malignant melanoma, 371

DAG *see* Dianhydrogalactitol

Daunomycin *see* Daunorubicin

Daunorubicin

cellular and plasma kinetics of, given by two methods of administration in a patient with acute leukemia, 2085

comparative cardiac and renal toxicity of, in the rat and rabbit, 395

toxicity reduction by conjugation to dextran, 107

10-Deaza-aminopterin

biochemical and pharmacologic properties of a new folate analog, 351

3-Deazaguanine

a candidate drug for the chemotherapy of breast carcinomas? 1853

3-Deazauridine

daily \times 5 schedule of: phase I trial and pharmacokinetics of, 81

Decadron *see* Dexamethasone

2'-Deoxycoformycin

and 9- β -D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia, 253

comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs and tubercidin and adenosine alone or in combination with, 317

- relationship of 5'-nucleotidase activity and antileukemic effect in therapy with, 387
- 5'-Deoxy-5-fluorouridine**
a new fluoropyrimidine derivative: a phase I clinical study, 1307
- Depo Provera** *see* Medroxyprogesterone
- DES** *see* Diethylstilbestrol
- Dextran**
toxicity reduction of daunorubicin by conjugation to, 107
- Dianhydrolulcitol** *see* Dianhydrogalactitol
- Dianhydrogalactitol (DAG)**
in advanced renal cell carcinoma: a Southwest Oncology Group phase II trial, 1231
and carmustine (BCNU) combination in the treatment of primary brain tumors recurring after irradiation, 1647
and cisplatin in combination for advanced cancer of the uterine cervix, 1809
clinical and pharmacologic evaluation of split-dose intermittent therapy with, 283
- Dibromodulcitol** *see* Mitolactol
- Dihydrofolate reductase**
malnutrition effect on tissue levels of, and toxicity of methotrexate, 85
- Dihydroxyanthracenedione (DHAD)** *see* Mitoxantrone
- Dimethyl sulfoxide (DMSO)**
prevention of doxorubicin-induced skin ulcers in the rat and pig with, 1371
- DNA**
-doxorubicin complex: a phase I clinical trial, 2033
- DON (6-diazo-5-oxo-norleucine)**
administered by 5-day courses: a phase I trial, 1215
in patients with previously treated advanced lung cancer: a phase II study, 1665
- Dopamine**
therapeutic effect of infusion on human malignant melanoma, 1657
- Doxorubicin**
altered hepatic disposition of, in the perfused rat liver at hyperthermic temperatures, 1357
with BCNU and cyclophosphamide, combination chemotherapy for bronchogenic carcinoma: a pilot study of the Southeastern Cancer Study Group, 199
with cisplatin, cyclophosphamide, and vindesine, combination chemotherapy for non-small cell lung cancer, 247
combined chemotherapy with bleomycin, vinblastine, and dacarbazine, and radiotherapy for advanced lymphoepithelioma, 1207
with cyclophosphamide, carmustine (BCNU), and prednisone in the treatment of multiple myeloma resistant to melphalan, 451
with cyclophosphamide and methotrexate (CAM), random prospective study of combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer, 2005
with cyclophosphamide and methotrexate in the treatment of advanced prostate cancer, 1797
with cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine, compared with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin in the treatment of diffuse histiocytic lymphoma, 1279
- cytotoxicity enhanced by local anesthetics in a human melanoma cell line, 121
-DNA complex: a phase I clinical trial, 2033
4'-epi- derivative of, activity on normal hematopoietic precursor cells in mice, 2061
4'-epi- derivative in metastatic renal cancer: a phase II study, 1219
4'-epi- derivative in patients with advanced colorectal carcinoma: a phase II study, 1757
4'-epi- derivative, pharmacokinetic studies in cancer patients with normal and impaired renal function and with hepatic metastases, 1819
with 5-FU and mitomycin (FAM) and chlorozotocin, a phase II study in advanced measurable pancreatic cancer, 2095
with 5-FU, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas: a phase I-II study, 1613
ganglioneuropathy in rabbits and rhesus monkey due to high cumulative doses of, 1349
high-dose: an exploration of the dose-response curve in human neoplasia, 493
increased relative effectiveness of, against slowly proliferating Sarcoma 180 cells after prolonged drug exposure, 1159
-induced skin ulcers in the rat and pig, prevention with dimethyl sulfoxide (DMSO), 1371
inhibition of cardiac guanylate cyclase by, and some of its analogs: possible relationship to cardiotoxicity, 311
local and systemic toxicity resulting from large-volume ip administration in the rat, 157
with mitomycin and 5-FU in the treatment of hormone-resistant stage D prostate cancer: a preliminary report, 57
and mitomycin in non-small cell bronchogenic carcinoma: a phase II study, 177
and mitomycin, response in cholangiocarcinoma: a case report, 209
with or without radiation and with or without levamisole immunotherapy in limited squamous cell carcinoma of the lung: a Southwest Oncology Group randomized study, 1113
with radiation therapy in malignant pleural mesothelioma, 1605
safety compared to mitoxantrone, a new anticancer compound: clinical observations, 1139
safety compared to mitoxantrone, a new anticancer compound: histologic and ultrastructural pathology, 1145
as a single agent in patients with previously untreated breast cancer: experience of the Eastern Cooperative Oncology Group, 1594
subcutaneous reaction due to intra-arterial infusion of, 2000
therapy for advanced islet cell carcinoma: a phase II study, 1567
vincristine, BCNU, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 1267
with vincristine, prednisolone, and cyclophosphamide (VAP-cyclo): a short intensive regimen for advanced breast cancer, 1999
-vincristine therapy for Wilms' tumor: invited comment on the Milwaukee pilot study, 1795
-vincristine therapy for Wilms' tumor: a pilot study, 1791

Droperidol

effective control of cisplatin-induced nausea using high-dose steroids and, 243

DTIC *see* Dacarbazine

E**Ellipticine**

isolation and properties of Chinese hamster lung cells resistant to derivatives of, 327

Ellipticinium

hydroxy-9-methyl-2- derivative for osseous metastases from breast cancer: a 5-year experience, 1909

Endoxan *see* Cyclophosphamide**Esophageal cancer** *see* Cancer, esophageal**Estracyt**

in advanced breast cancer, a pilot study, 581

Etoposide (VP-16-213)

in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group phase II study, 1669

treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and, 267

unusual reaction to, and avoidance by prolonged infusion, 409

Etoprine

and metoprine, evaluation in the avian sarcoma virus glioma, rat model, 99

F**FAM (5-FU, doxorubicin, and mitomycin).**

and chlorozotocin, a phase II study in advanced measurable pancreatic cancer, 2095

5-Fluorouracil *see* 5-FU**5-FU**

with 1-(aminomethyl)-3-(2-chloroethyl)-3-nitrosourea (ACNU) and mitomycin (FUM) for carcinoma of the pancreas, 1645

and allopurinol: toxicity modulation and phase II results in colon cancer, 1133

alone or combined with mitomycin and cytarabine (MFC), randomized comparison in the treatment of advanced gastric cancer, 1263

anticipatory vomiting in women with breast carcinoma receiving adjuvant chemotherapy with cyclophosphamide, methotrexate and, 1601

cerebrospinal fluid versus serum concentrations of allopurinol, oxypurinol, and, during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation, 571

clinical trial of cisplatin and, as initial treatment for advanced squamous cell carcinoma of the head and neck, 471

combined with hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts, 1201

combination chemotherapy in patients with advanced colorectal carcinoma previously treated with, 2093

combination therapy with continuous-infusion PALA and bolus-injection: a phase II trial, 200

with doxorubicin and mitomycin (FAM) and chlorozotocin,

a phase II study in advanced measurable pancreatic cancer, 2095

with doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas: a phase I-II study, 1613

effects on hematopoietic stem cells in Friend murine leukemia virus-infected mice undergoing chemotherapy, 1949

with hexamethylmelamine, cyclophosphamide, methotrexate, and cisplatin-CAF in refractory ovarian cancer, 1233

with high-dose folinic acid (leucovorin) for treatment of advanced colorectal and gastric adenocarcinomas: a pilot study, 1803

intra-arterial chemotherapy combined with radiation therapy for treatment of localized adenocarcinoma of the pancreas: a Southwest Oncology Group study, 549

and methotrexate for recurrent head and neck cancer, 1925

-methotrexate sequential therapy in advanced measurable colorectal cancer: a phase II study, 1563

and methotrexate, sequentially, in the treatment of colorectal cancer, 1553

with mitomycin and doxorubicin in the treatment of hormone-resistant stage D prostate cancer: a preliminary report, 57

modulation of toxicity of, with high-dose allopurinol: phase I trial of an outpatient dose schedule, 1723

nasal cartilage necrosis following high-dose: a case report, 1884

and PALA, pilot study in patients with advanced cancer, 77

with prednimustine and methotrexate (PMF): a pilot study, 2081

with vindesine and mitomycin (FEMi) in the treatment of extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung: a Southwest Oncology Group study, 553

Folinic acid *see* Leucovorin**Ftorafur**

and cyclophosphamide combination chemotherapy against advanced L1210 murine leukemia, 1631

G**Gallium nitrate**

in advanced soft tissue and bone sarcomas: a Southwest Oncology Group study, 1673

in breast cancer: a Southwest Oncology Group phase II study, 1591

Gastrointestinal cancer *see* Cancer, gastrointestinal**Germ cell cancer** *see* Cancer, germ cell**Glutaminase-asparaginase**

succinylated *Acinetobacter*, clinical evaluation in adult leukemia, 1479

Glycine

N-diazooacetyl derivatives of phenylalanine and, antitumor activity against P388 leukemia and B16 melanoma in mice, 179

Guanylate cyclase

inhibition of cardiac, by doxorubicin and some of its analogs: possible relationship to cardiotoxicity, 311

lack of correlation between effects of anthracyclines on in vitro cardiac, and on in vivo cardiotoxicity, 1677

H

Head and neck cancer *see* Cancer, head and neck

Hexamethylmelamine

-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer, 1233
and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy, 1285
distribution in patients with ovarian and other pelvic cancers, 231
with mitomycin and vindesine as second-line treatment for small cell cancer of the lung, 1873
parenteral formulation of, potentially suitable for use in man, 1579
and pentamethylmelamine, tissue distribution in M5076/73A ovarian cancer-bearing mice, 127

Hodgkin's disease

anatomic substages of stage IIIA: followup of a collaborative study, 733
characteristics of cell lines, 615
changing patterns of, at autopsy: a 25-year experience at the National Cancer Institute, 1953-1978, 653
chemotherapy for advanced: conclusions from the Southeastern Cancer Study Group, 899
chemotherapy and combined modality therapy for: a progress report on Cancer and Leukemia Group B studies, 835
chemotherapy for: the remaining challenges, 925
in children: treatment results with MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) and low-dose, extended-field irradiation, 949
chromosomes in, 639
collaborative clinical trial for stage I and II: significance of mediastinal and nonmediastinal disease in laparotomy- and nonlaparotomy-staged patients, 775
combined modality therapy for advanced: long-term followup data, 871
complications of treatment of, in children, 977
conclusions from clinical trials of the Southwest Oncology Group, 847
cyclic delivery of MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) combinations in stage IV: rationale, background studies, recent results, 881
with direct extension into pulmonary parenchyma from a mediastinal mass: a presentation requiring special therapeutic considerations, 717
distinguishing features of the immunology of, in children, 969
effect of age on therapeutic response and survival in advanced, 889
growth factors in, 633
histochemistry of, 609
imaging techniques for staging abdominal, 697
immunohistochemical analysis of the distribution of lymphocyte subpopulations in, 667

immune status of untreated patients with, and prognosis, 701
implications of persistent T cell abnormalities for the etiology of, 681
influence of mediastinal adenopathy on site and frequency of relapse in patients with, 809
intergroup study of stages I and II in children: a preliminary report, 937
late effects of radiation therapy in the treatment of, 991
long-term cardiovascular evaluation of patients with, treated by thoracic mantle radiation therapy, 1003
long-term complications of MOPP chemotherapy in patients with, 1015
mistaken clinical and pathologic diagnosis of: a Southwest Oncology Group Study, 645
multidisciplinary treatment of advanced, by an alternating chemotherapeutic regimen of MOPP/ABVD and low-dose radiation therapy restricted to originally bulky disease, 907
patterns of care outcome studies in: results of the national practice and implications for management, 805
pathologist's role in management of patients with, 675
posttreatment laparotomy as a guide to management in patients with, 759
possible origin of the Reed-Sternberg cell from an interdigitating reticulum cell, 601
prognostic factors in pathologic stage III, 743
prognostic significance of mediastinal mass in childhood, 961
radiotherapy versus combined modality treatment of stage I and II, 799
results of lung irradiation for patients with large mediastinal masses and/or hilar disease, 819
results of treating without a policy of laparotomy staging, 717
role of radiation therapy in the treatment of, 915
second malignancies complicating: a Southwest Oncology Group 10-year followup, 1023
second malignant neoplasms in patients successfully treated for: a Cancer and Leukemia Group B study, 1035
social class and age at diagnosis of: new epidemiologic evidence for the two disease hypothesis, 689
stage I and II: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP (mechlorethamine, vincristine, prednisone, and procarbazine), 789
strategic role of laparotomy in staging, 767
summary and future directions, 1045
surgical restaging of, 751
treatment of advanced: 10-year experience in the Eastern Cooperative Oncology Group, 855
treatment of stage IIIA, 827
Hydroxydaunorubicin *see* Doxorubicin
7-Hydroxymethotrexate
and methotrexate, pharmacokinetics following infusions of high-dose methotrexate, 1733
Hydroxyurea
and bleomycin combination chemotherapy in the treatment of advanced head and neck cancer, 1439
Hyperthermia
ultrasonic, and drugs in the therapy for human tumor xenografts, 1635

whole-body, and chemotherapy for treatment of patients with advanced, refractory malignancies, 259

Hypoxanthine

combined with 5-FU and allopurinol in chemotherapy for human colon adenocarcinoma xenografts, 1201

I

ICRF-159 *see* Razoxane

Imidazole-4-carboxamide dimethyltriazene *see* Dacarbazine

Immunotherapy

ip and chemotherapy in advanced epithelial ovarian cancer, 1981

radiation with or without doxorubicin chemotherapy and with or without levamisole, in limited squamous cell carcinoma of the lung: a Southwest Oncology Group randomized study, 1113

Staphylococcus aureus immunoperfusion: a phase I trial, 2027

Indicine-N-oxide

disposition in mice and monkeys, 183

Inosine dialdehyde *see* Diglycoaldehyde

Interferon

effects on C1300 mouse neuroblastoma, 1575

Isopropylamine platinum

studies on the pharmacokinetics and metabolism of, 509

Isotretinoin

activity against squamous cell cancers and preneoplastic lesions, 1315

K

Kaposi's sarcoma *see* Cancer, Kaposi's sarcoma

L

Lactulose

changes in intestinal permeability to, induced by cytotoxic chemotherapy, 1435

Leucovorin

comparison of protection from methotrexate toxicity by thymidine and, in human lymphoid cell lines, 2051

failure to reduce toxicity in massive vincristine overdose, 1967

high-dose, and 5-FU for treatment of advanced colorectal and gastric adenocarcinomas: a pilot study, 1803

rescue with methotrexate, doxorubicin, cyclophosphamide, vincristine, and cytarabine, compared with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin in the treatment of diffuse histiocytic lymphoma, 1279

Leukemia

acute

AMSA—a promising new agent in refractory, 1475
cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with, 2085

high-dose AMSA and autologous bone marrow transplantation in relapsed, 1991

trial of AMSA in 1596

adult

aclacinomycin A, a new anthracycline antibiotic: phase I-II evaluation in adults with refractory, 1619

succinylated *Acinetobacter* glutaminase-asparaginase in, clinical evaluation, 1479

central nervous system

aziridinylbenzoquinone (AZQ) treatment of, 2105

lymphoblastic

AMSA therapy for children with lymphoblastic malignancy, 593

nonlymphoblastic

results of aggressive chemotherapy for acute, in adults, 1917

marrow transplantation for patients with acute, who achieve a first remission, 1463

nonlymphocytic

5-azacitidine and zorubicin for patients with previously treated acute: a Cancer and Leukemia Group B pilot study, 563

chemotherapy sensitivity assessment of leukemic colony-forming cells with in vitro simultaneous exposure to multiple drugs: clinical correlations in acute, 1257

pyrazofurin and cytarabine combination in the treatment of refractory acute, 1397

myelocytic

comments on new approaches to therapy of acute, 1073

2'-deoxycoformycin (DCF) and 9- β -D-arabinosylfuranosyladenine (ara-A) in the treatment of refractory acute, 253

therapy for patients with acute, who enter remission: bone marrow transplantation or chemotherapy, 1467

myelogenous

role of intensive postinduction chemotherapy in the management of patients with acute, 1455

treatment of the blast crisis of chronic, with 5-azacitidine and VP-16-213, 267

myeloid

autologous bone marrow transplantation in acute, in relapse or in complete remission, 1983

Leukeran *see* Chlorambucil

Levamisole

or *Corynebacterium parvum* chemoimmunotherapy versus chemotherapy in advanced lung cancer, 1291

Liver cancer *see* Cancer, liver

Lomustine (CCNU)

inadvertent overdose with, followed by hematologic recovery, 1241

pulmonary fibrosis associated with: a case report, 1881

with vincristine, methotrexate, and procarbazine, treatment of relapsed small cell lung carcinoma, 1557

Lung cancer *see* Cancer, lung

Lycurim

and pyrazofurin, action on hepatoma 3924A cells in culture, 343

Lymphoepithelioma *see* Cancer, lymphoepithelioma

Lymphoma *see* Cancer, lymphoma

M

Malnutrition

effect on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat, 85

Mannitol

cisplatin hydration with and without diuresis in refractory malignant melanoma: a Southwest Oncology Group study, 31

Marihuana

contamination of cigarettes with pathogenic bacteria—possible source of infection in cancer patients, 589

Matulane *see* Procarbazine

Maytansine

with cisplatin and chlorozotocin in small cell lung carcinoma (EST 2578): a phase II study, 1417
in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group phase II study, 1587

Medroxyprogesterone

acetate (MPA), high-dose, in advanced chemotherapy-resistant ovarian carcinoma: a phase II study, 407
acetate (MAP), relative bioavailability after single high-dose administration in cancer patients, 2043
high-dose, in advanced male breast cancer, 1763
high-dose, for the treatment of advanced ovarian carcinoma, 1441
with tamoxifen in advanced renal cell cancer: a phase II study, 1773
and Yoshi 864 in adenocarcinoma of the kidney: a Southwest Oncology Group study, 1781

Megestrol acetate

in patients with advanced malignant melanoma: a phase II study, 1239

Melanoma *see* Cancer, melanoma

Melphalan

enhanced lymph node uptake of, following liposomal entrapment and effects on lymph node metastases in rats, 517
essential thrombocythemia: response during first year of therapy with radioactive phosphorus and: a Polycythemia Vera Study Group report, 1495
influence of renal failure on myelosuppressive effects of: Cancer and Leukemia Group B experience, 475
intermittent with prednisone versus intermittent carmustine (BCNU), cyclophosphamide, and prednisone in myeloma, 1273
multiple myeloma resistant to: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone, 451
with prednisone, cyclophosphamide, vincristine, and BCNU (M-2 protocol): combination chemotherapy for multiple myeloma, 1971

6-Mercaptopurine

fever due to, 1785

Methotrexate

anticipatory vomiting in women with breast carcinoma receiving adjuvant chemotherapy with cyclophosphamide, 5-FU and, 1601
with or without L-asparaginase: randomized phase II comparison in non-small cell cancer of the lung, 541
with bleomycin, cisplatin, and vincristine in advanced non-small cell bronchogenic carcinoma, 205

with CCNU, vincristine, and procarbazine, treatment of relapsed small cell lung carcinoma, 1557

combinations (COP or CHOP) in the treatment of previously untreated and treated lymphomas, 43

with cyclophosphamide and doxorubicin (CAM), random prospective study of combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer, 2005

with cyclophosphamide and doxorubicin in the treatment of advanced prostate cancer, 1797

effects compared with two nonclassic folic acid antagonists and cytarabine on hematopoietic precursor cells, 499

effect of malnutrition on toxicity of, and tissue levels of dihydrofolate reductase in the rat, 85

and 5-FU for recurrent head and neck cancer, 1925

5-FU sequential therapy in advanced measurable colorectal cancer: a phase II study, 1563

and 5-FU, sequentially, in the treatment of colorectal cancer, 1553

with hexamethylmelamine, cyclophosphamide, and 5-FU and cisplatin-CAF in refractory ovarian cancer, 1233

and 7-hydroxymethotrexate, pharmacokinetics following infusions of high-dose methotrexate, 1733

lack of efficacy of high-dose, by 30-hour infusion in patients with progressive small cell carcinoma of the lung, 1223

with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, and cytarabine, compared with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin in the treatment of diffuse histiocytic lymphoma, 1279

neurologic and cardiac toxicity following iv application of, 1561

with prednimustine and 5-FU (PMF): a pilot study, 2081

studies of Baker's antifol, razoxane and, in advanced gastric cancer: a Gastrointestinal Tumor Study Group report, 1713

treatment of neoplastic meningitis with intraventricular thiopeta and, 1549

Methyl-CCNU *see* Semustine

N-Methylformamide

studies of the pharmacology of, in mice, 1957

Methyl-GAG

in advanced colon cancer: a phase II trial of the Southwest Oncology Group, 2099

combination chemotherapy for patients with relapsed malignant lymphoma using teniposide (VM-26) and, 1121

in patients with malignant neoplasms: a phase I re-evaluation, 65

in the treatment of esophageal carcinoma: a phase II study, 1427

and vinblastine combination in the treatment of metastatic renal adenocarcinoma, 1585

Metoclopramide

control of dacarbazine-induced emesis with high-dose, in a preliminary trial, 2108

high-dose, in cancer chemotherapy-induced nausea and vomiting, 2107

Metoprine

and etoprine, evaluation in the avian sarcoma virus glioma, rat model, 99

Misonidazole

-induced peripheral neuropathy, dose-response curve for predicting, 1743

O-demethylation of, by rat liver microsomes, 1343

Mitolactol

in patients with metastatic melanoma: a phase II trial, 195
and semustine combination chemotherapy for advanced malignant melanoma: a phase II study, 1425

Mitomycin

with bleomycin, sequential combination in advanced cervical cancer: a Northern California Oncology Group study, 163
with cytarabine and 5-FU, randomized comparison in the treatment of advanced gastric cancer, 1263

with doxorubicin and 5-FU in the treatment of hormone-resistant stage D prostate cancer: a preliminary report, 57

and doxorubicin in non-small cell bronchogenic carcinoma: a phase II study, 177

and doxorubicin, reponse in cholangiocarcinoma: a case report, 209

with 5-FU and 1-(aminomethyl)-3-(2-chloroethyl)-3-nitrosourea (ACNU) (FUM) for carcinoma of the pancreas, 1645

with 5-FU and doxorubicin (FAM) plus chlorozotocin, a phase II study in advanced measurable pancreatic cancer, 2095

with 5-FU, doxorubicin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas: phase I-II study, 1613

with 5-FU and vindesine (FEMi) in the treatment of extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung: a Southwest Oncology Group study, 553

hemolytic-uremic syndrome associated with therapy, 457

with hexamethylmelamine and vindesine as second-line treatment of small cell cancer of the lung, 1873

-induced hemolytic uremic syndrome: case presentation and review of literature, 1244

with vinblastine and carmustine (BCNU) as third-line chemotherapy in refractory breast carcinoma: a pilot study, 559

Mitotane

modification of radiation damage in rat spinal cord by, 1545

Mitoxantrone

in advanced colorectal cancer: a phase II study, 1995

clinical and pharmacologic studies of, 1327

5-day schedule of: a phase I study, 1303

a phase II trial of, 1929

potential cardiotoxicity with, 1641

in previously untreated patients with colorectal adenocarcinoma: a Southwest Oncology Group phase II study, 1779

safety compared to doxorubicin: clinical observations, 1139

safety compared to doxorubicin: histologic and ultrastructural pathology, 1145

MOPP (mechlorethamine, vincristine, prednisone, and procarbazine)

multidisciplinary treatment of advanced Hodgkin's disease by alternating regimen of ABVD/MOPP and low-dose restricted radiation therapy, 907

stage I and II Hodgkin's disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of, 789

treatment results with low-dose, extended-field irradiation and, in childhood Hodgkin's disease, 949

Mycosis fungoides *see* Cancer, mycosis fungoides

Myeloma *see* Cancer, myeloma

Myleran *see* Busulfan

N

Neocarzinostatin *see* Zinostatin

Nitrogen mustard *see* Mechlorethamine

Nolvadex *see* Tamoxifen

O

Oncovin *see* Vincristine

Organ culture studies

prevention and reversal by a retinoid of 3,4-benzpyrene and cigarette smoke condensate-induced hyperplasia and metaplasia of rodent respiratory epithelia in, 1375

Ovarian cancer *see* Cancer, ovarian

Oxypurinol

cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol and, during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation, 571

P

PALA

and 5-FU: a phase II trial of combination therapy with bolus-injection 5-FU and continuous-infusion, 299

and 5-FU: pilot study in patients with advanced cancer, 77
in hypernephroma and urinary bladder cancer: a phase II trial, 2091

Pancreatic cancer *see* Cancer, pancreatic

Pentamethylmelamine

and hexamethylmelamine, tissue distribution in M5076/73A ovarian cancer-bearing mice, 127

a phase I trial of, 1227

Peplomycin

development and application of a radioimmunoassay for, 1365

Pharmacokinetics

of acivicin in plasma and cerebrospinal fluid, in Ommaya reservoir-bearing rhesus monkeys, 1333

of aziridinylbenzoquinone, clinical and pharmacologic studies, 1321

cisplatin nephrotoxicity and: a common circadian mechanism, 1933

dose-response curves for predicting misonidazole-induced peripheral neuropathy, 1743

doxorubicin 4'-epi derivative in cancer patients with normal and impaired renal function and with hepatic metastases, 1819

of high-dose methotrexate, effect of activated charcoal, 1169
and metabolism of *cis*-dichloro-*trans*-dihydroxy-bis-isopropylamine platinum(IV) in the dog, 509

methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate, 1733

of mitoxantrone, clinical and pharmacologic studies, 1327

and phase I trial of a daily \times 5 schedule of 3-deazauridine, 81

Phase I studies

aclacinomycin A, a new anthracycline antibiotic, in adults with refractory leukemia (phase I-II study), 1619
aclacinomycin A trial, 1127
L-alanosine using a daily \times 3 schedule, 73
m-AMSA administered as a continuous infusion (phase I-II study), 1813
bisantrene, clinical evaluation of, 1517
5-day schedule of mitoxantrone (dihydroxyanthracenedione), 1303
5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative, 1307
DON administered by 5-day courses, 1215
doxorubicin-DNA complex, 2033
5-FU and allopurinol: toxicity modulation and phase II results in colon cancer, 1133
5-FU, doxorubicin, mitomycin, and semustine combination (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas (phase I-II study), 1613
high-dose allopurinol modulation of 5-FU toxicity: trial of an outpatient dose schedule, 1723
indicine-N-oxide in patients with advanced cancer, 1509
isotopic immunoglobulin therapy for primary liver cancer: a phase I-II study, 289
methyl-GAG in patients with malignant neoplasms, 65
mitomycin, high-dose, with autologous bone marrow support, 277
PALA and 5-FU, pilot study in patients with advanced cancer, 77
pentamethylmelamine, 1227
and pharmacokinetics of a daily \times 5 schedule of 3-deazauridine, 81
13-cis-retinoic acid toxicity, 1759
of SOAz, 2039
spirogermanium given by infusion in a multiple-dose schedule, 173
Staphylococcus aureus immunoperfusion, 2027

Phase II studies

aclacinomycin A, a new anthracycline antibiotic, in adults with refractory leukemia (phase I-II study), 1619
AMSA, high-dose, and bone marrow rescue in patients with solid tumors, 385
AMSA in patients with advanced ovarian cancer, 1242
AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study, 1211
AMSA in patients with stage III-IV malignant melanoma, 1237
AMSA, prednisone, and chlorambucil (APC) in the treatment of refractory breast cancer: a Northern California Oncology Group study, 1235
AMSA in previously treated patients with stage III and IV ovarian cancer, 1589
AMSA in prostatic cancer, 208
AMSA in refractory breast cancer, 403
m-AMSA administered as a continuous infusion (phase I-II study), 1813
m-AMSA in disseminated prostatic carcinoma, 1993
m-AMSA in hepatocellular carcinoma: a Southwest Oncol-

ogy Group study, 1651
anguidine in gastrointestinal malignancies: a Southwest Oncology Group study, 381
aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia Group B trial, 1875
an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma, 2089
aziridinylbenzoquinone (AZQ) in head and neck cancer, 2097
bisantrene in advanced colorectal cancer: a Cancer and Leukemia Group B study, 1997
bisantrene for advanced hypernephroma, 1653
bisantrene in patients with renal cell carcinoma, 1869
bleomycin, intracavitary, in the management of malignant effusions: a multicenter study, 1903
chlorozotocin in malignant melanoma, breast cancer, and other solid tumors, 1229
chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report, 1431
cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578), 1417
combination therapy with continuous-infusion PALA and bolus-injection 5-FU, 299
cycloleucine, intermittent high-dose, in colorectal malignancies, 203
cyclophosphamide and prednisolone high-dose regimen in advanced non-Hodgkin's lymphoma of favorable histologic type, 377
doxynorleucine (DON) in patients with previously treated advanced lung cancer, 1665
dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study, 1231
dianhydrogalactitol (DAG) split-dose intermittent therapy, clinical and pharmacologic evaluation, 283
doxorubicin 4'-epi derivative in patients with advanced colorectal carcinoma, 1757
doxorubicin and mitomycin in non-small cell bronchogenic carcinoma, 177
doxorubicin therapy for advanced islet cell carcinoma, 1567
4'-epi-doxorubicin in metastatic renal cancer, 1219
hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience, 1909
etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study, 1669
5-FU and allopurinol: toxicity modulation and phase II results in colon cancer, 1133
5-FU, doxorubicin, mitomycin, and semustine combination (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas (phase I-II study), 1613
gallium nitrate in breast cancer: a Southwest Oncology Group study, 1591
high-dose megestrol acetate in patients with advanced malignant melanoma, 1239
isotretinoin activity against squamous cell cancers and preneoplastic lesions, 1315
isotopic immunoglobulin therapy for primary liver cancer: a phase I-II study, 289
maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study, 1587
medroxyprogesterone acetate (MPA), high-dose, in ad-

- vanced chemotherapy-resistant ovarian carcinoma, 407
- medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer, 1773
- methotrexate and 5-FU use for recurrent head and neck cancer, 1925
- methyl-GAG in advanced colon cancer: a phase II trial of the Southwest Oncology Group, 2099
- methyl-GAG in the treatment of esophageal carcinoma, 1427
- methyl-GAG and vinblastine combination in the treatment of metastatic renal adenocarcinoma, 1585
- mitolactol in patients with metastatic melanoma, 195
- mitolactol and semustine combination chemotherapy for advanced malignant melanoma, 1425
- mitoxantrone in advanced colorectal cancer, 1995
- mitoxantrone in previously untreated patients with colorectal adenocarcinoma: a Southwest Oncology Group study, 1779
- mitoxantrone trial, 1929
- prednimustine in children with recurrent cancer: a Children's Cancer Study Group report, 1583
- procarbazine in small cell carcinoma of the lung, 273
- randomized comparison of methotrexate with or without L-asparaginase in non-small cell cancer of the lung, 541
- razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy, 557
- results of aggressive chemotherapy for acute nonlymphoblastic leukemia in adults, 1917
- sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer, 1563
- spiogeranium in advanced epithelial carcinoma of the ovary, 1675
- spiogeranium in breast adenocarcinoma: a Cancer and Leukemia Group B study, 1667
- tamoxifen in malignant melanoma, 1447
- tamoxifen in patients with metastatic malignant melanoma, 1437
- thioprolin in advanced epidermoid head and neck tumors, 585
- vinblastine, bleomycin, and cisplatin combination in advanced malignant melanoma, 567
- vinblastine, divided-dose, in non-small cell bronchogenic carcinoma, 171
- vindesine in patients with advanced breast cancer, 1729
- vindesine for patients with advanced colorectal carcinoma, 583
- VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study, 405
- Yoshi 864 in epithelial ovarian carcinoma: a Gynecologic Oncology Group study, 1775
- Phase III studies**
- intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma, 1273
- Phenylalanine**
- N*-diazocetyl derivatives of glycine and, antitumor activity against P388 leukemia and B16 melanoma in mice, 179
- L-Phenylalanine mustard** *see* Melphalan
- Phosphoramidate mustard**
- vomiting induced by cyclophosphamide and, in cats, 1625
- Prednimustine**
- in advanced soft tissue sarcomas, 201
- in children with recurrent cancer: a Children's Cancer Study Group report, 1583
- with methotrexate and 5-FU (PMF): a pilot study, 2081
- Prednisolone**
- and cyclophosphamide, high-dose regimen in advanced non-Hodgkin's lymphoma of favorable histologic type, 377
- with vincristine, doxorubicin, and cyclophosphamide (VAP-Cyclo): a short intensive regimen for advanced breast cancer, 1999
- Prednisone**
- with AMSA and chlorambucil (APC) in the treatment of refractory breast cancer: a Northern California Oncology Group study, 1235
- with cisplatin, BCNU, and cyclophosphamide in multiple myeloma, 237
- with cisplatin and cyclophosphamide, therapy for stage D prostatic cancer, 1403
- with cyclophosphamide, doxorubicin, vincristine, and bleomycin, compared with doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine in the treatment of diffuse histiocytic lymphoma, 1279
- with cyclophosphamide and vincristine, combination chemotherapy in TNM-classified stage IV mycosis fungoides, 167
- with doxorubicin, cyclophosphamide, and carmustine (BCNU) in the treatment of multiple myeloma resistant to melphalan, 451
- intermittent with carmustine (BCNU), cyclophosphamide, and, versus intermittent melphalan and prednisone in myeloma, phase III study, 1273
- with melphalan, cyclophosphamide, vincristine, and BCNU (M-2 protocol): combination chemotherapy for multiple myeloma, 1971
- treatment of advanced plasma cell myeloma with alternate-day, and weekly cyclophosphamide, 1413
- vincristine, BCNU, and doxorubicin (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 1267
- Procarbazine**
- with CCNU, vincristine, and methotrexate, treatment of relapsed small cell lung carcinoma, 1557
- serial analysis of melanoma growth kinetics in a patient receiving bleomycin and: comparison of tumor volume, flow cytometry, and thymidine labeling techniques, 529
- Prostatic cancer** *see* Cancer, prostatic
- Provera** *see* Medroxyprogesterone
- Public policy**
- the development of new cancer drugs: a joint venture by the National Cancer Institute and the Food and Drug Administration, 1705
- Pyrazofurin**
- and cytarabine, treatment of refractory acute nonlymphocytic leukemia with a combination of, 1397
- and lycurim, action on hepatoma 3924A cells in culture, 343

R

Radiation therapy

- cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol and, during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and, 571
- chemotherapy combination used prior to, for locally advanced squamous cell carcinoma of the head and neck, 1421
- chemotherapy and radical, combination for primary squamous cell carcinoma of the anal canal, 489
- combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after, 1647
- and combined chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine for advanced lymphoepithelioma, 1207
- combined with intra-arterial 5-FU chemotherapy for treatment of localized adenocarcinoma of the pancreas: a Southwest Oncology Group study, 549
- versus combined modality treatment of stage I and II Hodgkin's disease, 799
- doxorubicin with or without, and with or without levamisole immunotherapy in limited squamous cell carcinoma of the lung: a Southwest Oncology Group randomized study, 1113
- with doxorubicin in malignant pleural mesothelioma, 1605
- essential thrombocythemia: response during first year of therapy with radioactive phosphorus and melphalan: a Polycythemia Vera Study Group report, 1495
- with 5-FU infusion and allopurinol, 571
- involved-field versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) in stage I and II Hodgkin's disease, 789
- isotopic immunoglobulin therapy for primary liver cancer: a phase I-II study, 289
- late effects of, in the treatment of Hodgkin's disease, 991
- long-term cardiac vascular evaluation of patients with Hodgkin's disease treated by thoracic mantle irradiation, 1003
- multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABVD and low-dose radiation therapy restricted to originally bulky disease, 907
- results in 15 patients with primary non-Hodgkin's lymphoma of bone treated by systemic chemotherapy combined with, 1859
- results of lung irradiation for patients with large mediastinal masses and/or hilar disease, 819
- role in the treatment of Hodgkin's disease, 915
- treatment results in children with Hodgkin's disease using MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) and low-dose, extended-field, 949
- upper hemibody and local chest irradiation as consolidation following response to high-dose induction chemotherapy for small cell bronchogenic carcinoma—a pilot study, 1609

Radioimmunoassay

- for peplomycin, 1365

Razoxane

- in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy, 557
- studies of Baker's antifol, methotrexate and, in advanced gastric cancer: a Gastrointestinal Tumor Study Group re-

port, 1713

Renal cell cancer *see* Cancer, renal cell

13-*cis*-Retinoic acid

- toxicity of: a phase I study, 1759

Rubidazone *see* Zorubicin

Rubidomycin *see* Daunorubicin

S

Scopolamine

- versus placebo administered by transdermal patch for the control of cisplatin-induced emesis: results of a randomized double-blind crossover trial, 1975

Semustine

- with 5-FU, doxorubicin, and mitomycin (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas: phase I-II study, 1613
- and mitolactol combination chemotherapy for advanced malignant melanoma: a phase II study, 1425

SOAz

- a phase I study of, 2039

Soft tissue cancer *see* Cancer, soft tissue

Spirogermanium

- in advanced epithelial carcinoma of the ovary: a phase II study, 1675
- in breast adenocarcinoma: a Cancer and Leukemia Group B phase II study, 1667
- by infusion in a multiple-dose trial: a phase I study, 173

Staphylococcus aureus Cowan I

- immunoperfusion with: a phase I trial, 2027

Statistics

- guidelines for medical research reports, 217

Steroids

- effective control of cisplatin-induced nausea using droperidol and high-dose, 243

Streptozocin

- pharmacology and toxicity of ip, in ovarian cancer: a case study, 1595
- review of its pharmacology, efficacy, and toxicity, 427

T

Tamoxifen

- in malignant melanoma: a phase II study, 1447
- with medroxyprogesterone acetate in advanced renal cell cancer: a phase II study, 1773
- in metastatic melanoma, Southwest Oncology Group experience with, 1680
- before and after orchiectomy in advanced male breast cancer, 1882
- in patients with metastatic malignant melanoma: a phase II study, 1437
- response to oophorectomy after failure of, in a premenopausal patient, 1869
- in the treatment of metastatic malignant melanoma, 1771
- trial at a 40-mg daily dose after disease progression during therapy at a 20-mg daily dose, 1445

Taxol

tubulin-dependent biochemical assay for, and application to measurement of the drug in serum, 1381

T-cell cancer *see* Cancer, T-cell

Teniposide (VM-26)

combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and, 1121

comparative trial of two combination chemotherapy regimens based on, for the treatment of advanced malignant lymphomas, 2021

in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group phase II study, 405

vincristine and, comparison in chemotherapy for non-Hodgkin's lymphoma, 43

Testicular cancer *see* Cancer, testicular

6-Thioguanine

response of hypereosinophilic syndrome to cytarabine and, 545

Thioprolone

in advanced epidermoid head and neck tumors: a phase II trial, 585

Thiotepa

treatment of neoplastic meningitis with intraventricular methotrexate and, 1549

Thrombocytopenia

essential (ET): response during first year of therapy with melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report, 1495

Thymidine

comparison of protection from methotrexate toxicity by folinic acid and, in human lymphoid cell lines, 2051

Triazinate *see* Baker's antifol

3,4,5-Trihydroxybenzohydroxamic acid (VF-122)

cytotoxic and cell kinetic effects of, in hepatoma 3924A cells, 2071

Tubercidin

comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs and adenosine and, alone or in combination with 2'-deoxycytosine, 317

Tuberculosis

possible relationship between previous, and long-term survival after solid tumor chemotherapy, 206

Tubulin

-dependent biochemical assay for taxol and application to measurement of the drug in serum, 1381

Tumor systems, animals

B16 melanoma

antitumor activity of *N*-diazooacetyl derivatives of glycine and phenylalanine against mouse P388 leukemia and, 179

C1300 mouse neuroblastoma

effects of interferon on, 1575

colon adenocarcinoma xenografts

combinations of 5-FU, hypoxanthine, and allopurinol in chemotherapy for human, 1201

Dunning R3327H prostatic adenocarcinoma

response to radiation and various chemotherapeutic drugs, 1837

Friend murine leukemia virus

hematopoietic stem cells in infected mice undergoing chemotherapy: effects of 5-FU, 1949

human tumor xenografts

ultrasonic hyperthermia and drugs in the therapy for, 1635

L1210 leukemia

antitumor activity and toxicity of cisplatin analogs, 135

combination chemotherapy with cyclophosphamide and fltorafur against advanced murine, 1631

leukemia, acute

chemoimmunotherapy for autochthonous, in rat, 391

Lewis lung carcinoma

prophylactic antimetastatic treatment with arylidimethyltriazines as adjuvants to surgical tumor removal in mice bearing, 115

M5075/74A ovarian cancer

hexamethylmelamine and pentamethylmelamine tissue distribution in mice bearing, 127

M5076/73A ovarian reticular cell sarcoma of the mouse activity of 1-*p*-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt in, 1945

murine leukemias and solid tumors

vinyllogous carbinolamine tumor inhibitors, activity of bis(acyloxymethyl) derivatives of pyrroles and pyrrolizines against a panel of, 91

P388 leukemia

antitumor activity of *N*-diazooacetyl derivatives of glycine and phenylalanine against mouse B16 melanoma and, 179

9L rat brain tumor

combination chemotherapy for, 575

rat glioma

evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus model of, 99

3924A rat hepatoma

cytotoxic and cell kinetic effects of 3,4,5-trihydroxybenzohydroxamic acid (VF-122) in, 2071

transplantable tumors of mice

response to anthracenedione derivatives alone and in combination with clinically useful agents, 1187

U

Urinary tract cancer *see* Cancer, urinary tract

V

VAB-3

combination chemotherapy in primary mediastinal germ cell tumors, 1405

VAP-Cyclo (vincristine, doxorubicin, prednisolone, and cyclophosphamide)

a short intensive regimen of chemotherapy with, for advanced breast cancer, 1999

Velban *see* Vinblastine

Vinblastine

with bleomycin and cisplatin, treatment of advanced malignancy

nant melanoma with, 1299
 combination with bleomycin and cisplatin in advanced malignant melanoma: a phase II study, 567
 combined chemotherapy with doxorubicin, bleomycin, and dacarbazine, and radiotherapy for advanced lymphoepithelioma, 1207
 divided dose in non-small cell bronchogenic carcinoma: a phase II study, 171
 failure of 5-day infusion in the treatment of patients with advanced refractory breast cancer, 1783
 and methyl-GAG combination in the treatment of metastatic renal adenocarcinoma, 1585
 with mitomycin and carmustine (BCNU) as third-line chemotherapy in refractory breast carcinoma: a pilot study, 559
 with vincristine and vindesine, effect on neutrophil phagocytosis and iodination, 505

Vincristine
 acute vascular episodes associated with therapy for carcinomas of the upper aerodigestive tract with bleomycin, cisplatin, and, 369
 BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study, 1267
 with bleomycin, cisplatin, and methotrexate in advanced non-small cell bronchogenic carcinoma, 205
 with carmustine (BCNU) and bleomycin in patients with squamous cell bronchial carcinoma resistant to cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP), 1877
 with CCNU, methotrexate, and procarbazine, treatment of relapsed small cell lung carcinoma, 1557
 with cyclophosphamide, doxorubicin, prednisone, and bleomycin, compared with doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine in the treatment of diffuse histiocytic lymphoma, 1279
 with cyclophosphamide and prednisone (CVP), combination chemotherapy in TNM-classified stage IV mycosis fungoides, 167
 with doxorubicin, cyclophosphamide, methotrexate with leucovorin rescue, and cytarabine, compared with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin in the treatment of diffuse histiocytic lymphoma, 1279
 with doxorubicin, prednisolone, and cyclophosphamide (VAP-Cyclo): a short intensive regimen for advanced breast cancer, 1999
 -doxorubicin therapy for Wilms' tumor: invited comment on the Milwaukee pilot study, 1795
 -doxorubicin therapy for Wilms' tumor: a pilot study, 1791
 massive overdose of: failure of leucovorin to reduce toxicity, 1967
 with melphalan, prednisone, cyclophosphamide, and BCNU (M-2 protocol): combination chemotherapy for multiple myeloma, 1971
 teniposide and, comparison in chemotherapy for non-Hodgkin's lymphoma, 43
 with vinblastine and vindesine, effect on neutrophil phagocytosis and iodination, 505

Vindesine

-associated angina and ECG changes, 587
 with cisplatin, doxorubicin, and cyclophosphamide, combination chemotherapy for non-small cell lung cancer, 247
 an effective agent in the treatment of non-small cell lung cancer, 1709
 with 5-FU and mitomycin (FEMi) in the treatment of extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung: a Southwest Oncology Group study, 553
 with hexamethylmelamine and mitomycin as second-line treatment of small cell cancer of the lung, 1873
 monochemotherapy for non-small cell lung cancer: a report of 45 cases, 1409
 overdose of, 1247
 in patients with advanced breast cancer: a phase II study, 1729
 for patients with advanced colorectal carcinoma: a phase II evaluation, 583
 in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung, 305
 with vincristine and vinblastine, effect on neutrophil phagocytosis and iodination, 505

VM-26 *see* Teniposide
 VP-16-213 *see* Etoposide

W

Wilms' tumor *see* Cancer, Wilms' tumor

Y

Yoshi 864

in epithelial ovarian carcinoma: a Gynecologic Oncology Group phase II clinical study, 1775
 and medroxyprogesterone acetate in adenocarcinoma of the kidney: a Southwest Oncology Group study, 1781


Z

Zinostatin

severe toxicity and death associated with administration of, 410

Zorubicin

and 5-azacitidine for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study, 563



Author Index

A

Aabo K, 273, 407
Abe M, 1645
Abele R, 1307
Abeloff MD, 457, 1601, 1880
Abrams S, 171
Abramson N, 1273
Adair S, 1791
Adjizian JC, 1983
Adolphson CC, 209
Advani SH, 1169
Aherne GW, 1365
Ahmann DL, 567, 1239, 1425, 2089
Aisner J, 221, 1127, 1237, 1557, 1773, 1875
Ajani JA, 1227, 1987
Al-Sarraf M, 31, 471, 1993
Alberto P, 1307
Alberts DS, 1315
Alexanian R, 1267
Alison RE, 717
Altman SJ, 1781
Amare M, 1257, 1267
Ambrus JL, 201
Ames MM, 283, 1579
Amrein PC, 1211
Anbar D, 1997
Anderson J, 2021
Anderson JL, 493
Anderson KC, 1929
Anderson RM, 259
Anderson T, 1229, 1975
Anderson WK, 91
Andrysiak T, 589
Anku V, 2106
Anson N, 1885
Appelbaum FR, 1397, 1863
Applefield MM, 1003, 1127
Ardman B, 1785
Arlin ZA, 907, 1479, 1619
Armitage JO, 1917
Arnold AM, 1719
Arnold S, 147, 157
Arnon R, 107
Arseneau JC, 1285
Arthur D, 1683
Ashford RFU, 1884
Aunan SB, 1917
Austerlitz J, 1879

B

Bacci C, 1859
Bachur NR, 339
Bae E, 1219
Bains M, 1427
Bainton DF, 609
Bajetta E, 1299
Bakemeier RR, 855
Baker LH, 203, 371, 1231, 1447, 1591, 1673
Balcerzak SP, 253
Baldini L, 179
Balducci L, 31, 1231
Ballin A, 2000
Ban J, 343, 2071
Band PR, 1759
Barbieri A, 585
Barlock AL, 1229, 1767
Barlogie B, 529
Barnes JM, 855
Bartolucci A, 199, 899
Baum ES, 1583
Bean HA, 717
Beard R, 1635
Beckstead JH, 609
Bedikian A, 1517
Bell R, 377
Bellet RE, 557
Benjamin RS, 2033
Bennett JM, 855, 1273, 2021
Bennetts RW, 1613
Beran M, 385
Berard CW, 653, 2021
Berenberger J, 410
Bergerat JP, 1983
Bergsagel DE, 717
Berk PD, 1495
Bernhardt B, 1211
Bernstein A, 107
Berry J, 1403
Berry JP, 1529
Bertino JR, 871, 1279
Bertoli G, 115
Bertoni F, 1859
Besner JG, 1759
Betsill WL Jr, 1521
Bhathena BD, 371
Bhuchar VK, 375
Bianco AR, 1435

Bigner DD, 99
 Bjorkholm M, 701
 Blessing JA, 1669, 1775
 Blitt CD, 259
 Bliven SF, 1545
 Block ER, 359
 Block JB, 121
 Bloomfield CD, 563, 819, 835, 889
 Blumenschein GR, 385, 1517, 1641
 Boccardo F, 585
 Bodey GP, 73, 385, 1227, 1517, 1641, 1991, 2033
 Boesen E, 2081
 Bogliolo G, 2061
 Bolis G, 1233
 Bollag W, 1307, 1375
 Bonadonna G, 403, 881, 1299
 Bond WH, 2005
 Bonfante V, 881
 Bonnet JD, 1267, 1587, 1781
 Bonnem EM, 1661, 1995
 Bonomi PD, 1417
 Borch RF, 1889, 1933
 Borison HL, 363, 1625
 Børner O, 1437
 Borowitz MJ, 667
 Bottomley R, 381, 1267
 Bowles C, 2027
 Bowman D, 1553
 Braat PC, 1967
 Bradner WT, 135, 187, 1831
 Bramwell VHC, 1997
 Brandes LJ, 1413
 Bratt PM, 1889
 Breithaupt H, 1733
 Briere J, 1495
 Brille P, 1529
 Brindley C, 1957
 Brodovsky HS, 2021
 Broggin M, 127
 Bronson RT, 1349
 Brooks R, 1315
 Broun GO Jr, 237, 1409
 Browman GP, 2051
 Brown TC, 717
 Bruckner HW, 65, 1713
 Brunet R, 1563
 Brunner KW, 451, 1561, 1873
 Bruno S, 81
 Buckner CD, 1463
 Budillon G, 1435
 Budman DR, 171, 173, 1667, 1675, 1875
 Bui NB, 2107
 Bukowski RM, 381, 1651
 Bunn PA, 1223
 Burgert EO Jr, 961
 Burgess MA, 73, 1987, 2033
 Burns CP, 1917
 Burns D, 1431
 Burrichter H, 615
 Bush RS, 717
 Busutti L, 1763

Butler JJ, 789
 Buzzoni R, 1299
 Byfield JE, 571
 Byrne GE, 645

C

Cabanillas FF, 1227
 Cadman EC, 1279
 Cahn JY, 1983
 Calanog A, 1809
 Calderoni P, 1859
 Callahan K, 2097
 Camacho F, 1809
 Camaggi CM, 1819, 2043
 Camitta B, 1791
 Campanacci M, 1859
 Campbell TN, 1723
 Canellos GP, 1015, 1585
 Canobbio L, 585
 Canova N, 1819
 Cantrell JE, Jr, 1563
 Capizzi RL, 541
 Capuano G, 1435
 Carbone A, 167, 1207, 1971
 Carlin DA, 553
 Carney DN, 1223
 Carpenter JT, Jr, 209
 Carpentier Y, 2039
 Carrera CJ, 2085
 Carter SK, 163
 Casper E, 247
 Cass CE, 317
 Castellino RA, 697
 Catalano RB, 243, 557, 1609
 Cattani A, 2039
 Chahinian AP, 1291
 Champion LAA, 2013
 Champlin R, 277
 Chan H, 949
 Chang C-P, 91
 Chapman JD, 1837
 Chapman R, 1427
 Charcosset J-Y, 327
 Cheever MA, 1397
 Chello PL, 351
 Chen M, 1279
 Chen T, 381, 937, 1113, 1779
 Cheng E, 247
 Chenoweth L, 2005
 Chin HW, 211
 Chlebowski RT, 121
 Chohan V, 505
 Chou T-C, 1479
 Chua T, 717
 Chuang V, 1501
 Clark RA, 2108
 Clark RM, 717
 Clarkson BD, 907

Clift RA, 1463
 Coates AS, 19, 177, 1242
 Cobleigh MA, 1709
 Cocconi G, 1263
 Cohen GI, 1929
 Cohen HJ, 237
 Cohen MH, 1223
 Colby TV, 675
 Coldman AJ, 439
 Coleman M, 410, 563, 835, 1211, 1667
 Coleman MS, 253
 Collins JM, 157
 Collins RD, 1107
 Colombo N, 1233, 1681
 Colombo T, 127, 1945
 Coltman CA, Jr, 847, 1023, 1689
 Colvin M, 1487, 1625
 Comis R, 410
 Condon RE, 1357
 Coninx P, 2039
 Cooper MR, 419, 889, 1035
 Coral FS, 1455
 Corbett TH, 1187
 Corbitt R, 2027
 Corey PF, 91
 Cornwell GC, III, 475
 Cortes E, 1211
 Costanti B, 2043
 Costanzi J, 1680
 Costello W, 855
 Couette JE, 1909
 Coveney JR, 1889
 Cowan JD, 1779
 Cowens JW, 509
 Cox RS, 743
 Crain SM, 2097
 Creagan ET, 567, 1239, 1425, 1665, 2089
 Creaven PJ, 81, 509
 Creech RB, 1609
 Creech RH, 557, 1417
 Crivellari D, 559, 1207, 1971
 Croker BP, 667
 Crout JR, 1705
 Crowther D, 1771, 1997
 Cruz AB Jr, 549
 Cullinan SA, 2093
 Cummings BJ, 489, 1421
 Cummings G, 203, 371
 Cundiff D, 121
 Cunningham J, 809, 1015
 Curran J, 1387
 Cuttner J, 410

D

D'Amore F, 2061
 D'Angio G, 1795
 D'Incalci M, 121, 131, 1233, 1681, 1945
 D'Souza BJ, 2013

Dabich L, 751
 Dalley D, 717
 Dambra J, 243
 Damle SR, 1169
 Daubenspeck JA, 363
 Davis F, 633
 Davis HL, 1215
 Davis TE, 1285
 Dawes PJDK, 581
 Dean D, 2027
 Dean JC, 259
 DeGregorio MW, 2085
 Deisseroth A, 2027
 De Lena M, 403
 Delozier T, 1909
 De Múelenaere G, 1605
 De Sousa M, 969
 DeBellis R, 267
 DeBoer G, 717
 Decker DA, 1993
 DeGraw JI, 351
 DeLisi V, 1263
 DePersio EJ, 847
 DeVita VT, 653, 925
 DeWys WD, 1387
 Degnan TJ, 171, 173, 1675
 Delaney D, 541
 Delgado G, 1669, 1775
 Deneffrio J, 1439
 Denes AE, 199
 Denning B, 1729
 de Palo G, 1681
 Deprez-DeCampaneere D, 395
 Desai MH, 1371
 Deschamps M, 1759
 Dhabuwala CB, 1993
 Di Blasio, 1263
 Dick FR, 1917
 Dicke DA, 385
 Dicke KA, 1991
 Didolkar MS, 201
 Diehl V, 615
 Dietrich MF, 121
 Dillman RO, 1399
 Dillon MB, 1981
 Di Marco AR, 2043
 Dinapoli RP, 1647
 Dindogru A, 203
 Diorio G, 1759
 Dixon DO, 847, 1023, 1267
 Dombernowsky P, 273, 305, 407
 Donaldson SS, 977
 Donovan PB, 1495
 Dorfman RF, 675
 Dorick DM, 351
 Dorreen MA, 759
 Dorval T, 1803
 Dosik GM, 73
 Dosik H, 475
 Dougherty WJ, 1139
 Dowling R, 2027

Drelichman A, 471, 1993
Drewinko B, 529
Dukeman M, 1427
Dupont JC, 1596
Durant JR, 899

E

Eagan RT, 283, 1647, 1665
Eakin DL, 545
Earhart RH, 1215
Einhorn LH, 15, 1709, 2005
Einhorn N, 1285
Eisenberger MA, 1439
El Dareer SM, 183
Elford HL, 1825
Elfring GL, 1333
Elliott FG, 1837
Elson PJ, 405
Engelking C, 1797
Engstrom PF, 557
Ensminger WD, 493
Erlichman C, 489, 1783
Ervin TJ, 299
Ettinger DS, 289, 1417, 1487, 1981
Evans RC, 961
Everson LK, 2093
Eyre HJ, 1651

F

Faanes RB, 535
Fabian CJ, 1591, 1673, 1680, 2099
Faguet GB, 1495
Falkson G, 1605
Farber LR, 871, 1279
Farina P, 231
Farradji A, 1983
Faye L, 1653
Fearon F, 463
Fefer A, 1397
Ferrazzi E, 1274
Fetting JH, 363, 1487, 1601, 1625
Fine S, 489
Fiorentino MV, 1247
Fisher R, 937
Fisher RD, 25
Fisher RI, 681, 1229
Fixler H, 1349
Fleit JP, 1797
Fleming TR, 1101
Flesch M, 1983
Fletcher WS, 31, 1673
Flexner JM, 733
Floreczyk AP, 187, 1831
Floyd RA, 571
Folstein MF, 1487
Fonatsch C, 615

Fontana J, 1729
Foon KA, 1241
Forastiere AA, 1875, 1997, 2097
Ford J, 377
Ford RJ, 633
Fossa SD, 1219
Fosser V, 1247
Fox RM, 19, 177, 1242
Fraass BA, 991
Frankel S, 571
Freedman M, 949
Frei E III, 1455
Freireich EJ, 2033
Friedman MA, 163, 1235
Friedman RD, 339
Fritze D, 1785
Frondoza CG, 1535
Frustaci S, 1207
Fryer C, 937
Frytak S, 1665
Fuks JZ, 1237, 1773
Fuller LM, 775, 789, 937
Furnas BE, 1709
Furner R, 147

G

Gad-el-Mawla N, 1587
Gadgil SD, 1169
Gale RP, 277, 589
Gallagher CJ, 377
Galle P, 1529
Galligioni E, 167, 559, 1207, 1877, 1882
Gams RA, 899
Garattini S, 231, 1945
Garay GE, 1596
Garbe E, 2039
Garnick MB, 1585, 1929
Gasser AB, 1561
Gaynon PS, 1583
Geddes DM, 463
Gee TS, 907, 1479
Gehan E, 937, 1089
Gelber RD, 1594
Gelinias M, 1759
Gerdes J, 615
Germano G, 1307
Gerretson L, 163
Gescher A, 1957
Gherlinzoni F, 1859
Ghio R, 2061
Gilchrist GS, 937, 961
Gill DP, 545
Gill S, 1825
Gilmartin E, 1315
Ginsberg S, 1211, 1667
Giovannini M, 1819, 2043
Giraldi T, 115, 179, 1751
Girard C, 1759
Glass EC, 1683

Glassberg A, 163
 Glatstein E, 11, 991, 1743, 2027
 Glick JH, 855, 2021
 Glicklich M, 1791
 Glicksman AS, 835, 1035, 1545
 Glidewell OJ, 410, 835, 889
 Godfrey TE, 25
 Golbey R, 247, 1405, 1427
 Goldberg JD, 1291, 1495
 Goldhirsch A, 1873
 Goldie JH, 439
 Goldschmidt E, 1803
 Goldstein L, 410
 Golomb HM, 733, 827
 Gomez GA, 43
 Good RA, 969
 Goodman GE, 751
 Goodwin JW, 1257
 Goold MA, 1884
 Gordon G, 1145
 Gormley P, 1813
 Gorshein D, 809
 Gospodarowicz M, 717
 Gottlieb AJ, 563, 835, 889, 1035
 Goudsmit, R, 1967
 Gouveia Y, 1529
 Gralla RJ, 247, 2091, 2108
 Gramellini M, 1763
 Grant C, 1501
 Grant JM, 19
 Gray DP, 253
 Green JA, 1719
 Green MR, 1211, 1399
 Green SJ, 567, 1239, 1425, 2089
 Greenberg BR, 163
 Greenberg M, 949
 Greenberg MS, 563
 Greenberg PD, 1397
 Greenspan EM, 206
 Greenwald, E, 1449
 Grever MR, 253
 Gribbin M, 949
 Griffin JP, 1321
 Griffiths JC, 571
 Grigoletto E, 167, 559, 1207, 1877, 1971
 Griswold DP Jr, 1187
 Grochow LB, 1487
 Grogan TM, 653
 Groover RV, 1647
 Grossie VB Jr, 85, 1631
 Grossman B, 243
 Grossman SA, 1549
 Grozea PN, 553, 847
 Grumbine FC, 1981
 Guarino AM, 147, 157
 Guarneri D, 585
 Gudauskas GA, 439
 Guimaraes M, 463
 Gutensohn NM, 689
 Gutierrez PL, 339

H

Hacker MP, 1845
 Hagemeister FB, 789
 Hahn RG, 1567
 Halat MJ, 91
 Halberg F, 1933
 Hald I, 407
 Hall C, 1145
 Hall SW, 2033
 Halsall GM, 1903
 Hamel E, 1381
 Hammond D, 399, 1583
 Han T, 43
 Hankey BF, 653
 Hanks GE, 805
 Hannigan J, Jr, 163
 Hansen HH, 273, 305
 Hanson J, 1667
 Hanson W, 937
 Harper PG, 463
 Harpur ES, 1957
 Hart RD, 65
 Harvey HA, 1303
 Harwood AR, 489
 Haskell CM, 1241
 Hasselback R, 717
 Haut A, 1267
 Hayat M, 1803
 Haynie TP, III, 1501
 Hays D, 937
 Heelan R, 1427
 Heifetz LJ, 1613
 Heintz F, 615
 Heintz R, 1307
 Heit W, 615
 Heller R, 937
 Hellman S, 733, 809, 915
 Henderson BM, 1139
 Henderson E, 43, 81, 451
 Henderson IC, 1349
 Henderson SD, 575
 Hendrickson CA, 163
 Henle W, 1387
 Henry PH, 451
 Herman TS, 259
 Hermann RC Jr, 1647
 Hernandez E, 1981
 Heron JF, 1909
 Herring DF, 805
 Herrmann R, 1785
 Herve P, 1983
 Hewlett JS, 31
 Heyn R, 399
 Higgins G, 937
 Hill DL, 183
 Hiramoto RN, 237
 Ho DHW, 85
 Hobson AS, 1521
 Hoerni B, 2107

Hoeroff R, 1343
 Holcenberg JS, 387, 2105
 Holland JF, 65, 451, 835, 889, 1291, 1509
 Holm G, 701
 Holohan T, 2027
 Holyoke ED, 201
 Hong CB, 1845
 Hood CI, 359
 Hoogstraten B, 1231
 Hopkins HA, 1521
 Hoppe RT, 743
 Hørbov S, 305
 Hornbeck CL, 571
 Horton J, 1273
 Hoschner J, 471
 Houchens D, 1635
 Houghton JA, 1201
 Houghton PJ, 1201
 House BA, 1723
 Howell A, 1997
 Howell SB, 1133, 1723, 1825
 Howerd J, 1591
 Howser D, 1975
 Hrushesky WJM, 1933
 Hubbard SM, 1, 1975
 Huftalen JB, 135
 Humphrey RL, 1535
 Hutchison GB, 775
 Hutter JJ, 259, 593
 Hynes HE, 1591

I

Iafelice G, 1819
 Iaffaioli RV, 1435
 Iatropoulos MJ, 1145
 Ichiba K, 1645
 Ignoffo R, 1885
 Ihde DC, 1223
 Ilstrup DM, 961
 Ingle JN, 1665
 Israels LG, 1413

J

Jacobs C, 1925
 Jacobs J, 471
 Jacquemin-Sablon A, 327
 Jaenke R, 395
 Jaffrey IS, 1291
 James S, 1365
 James VC, 1139
 Jasmin C, 1803
 Jenkin D, 937, 949
 Jezekova D, 2039
 Johansson B, 701
 Johns DG, 1381
 Johnson DE, 57, 1501

Johnson G, 1387
 Johnsson J-E, 1441
 Johnston DA, 385, 789
 Johnston-Early A, 1223
 Jones AE, 759
 Jones AN, 91
 Jones FE, 1357
 Jones RD, 1613
 Jones SE, 645, 751, 847
 Joss RA, 1873
 Juret P, 1909

K

Kadin ME, 601
 Kalman AM, 1867
 Kamen BA, 2105
 Kant JA, 653
 Kaplan BH, 1285
 Kaplan HG, 1397
 Kaplan HS, 743, 977
 Kapp DS, 871
 Karakousis CP, 201
 Karlin DA, 1613
 Kasdorf H, 267
 Keane TJ, 489
 Kearsley JH, 1242
 Keating MJ, 1991
 Kefford RF, 19
 Kelsen DP, 247, 1427, 2091
 Kemeny N, 1757
 Kempin SJ, 907, 1619
 Kende G, 2000
 Kennedy BJ, 1683, 1933
 Khan AB, 2013
 Khandekar JD, 405, 1244
 Khato J, 517
 Khoo RKK, 1977
 Khwaja TA, 1853
 Kiang D, 1211
 Kidowaki T, 1575
 Kimler BF, 575
 King M, 1783
 Kinsella TJ, 421, 991
 Kinzie JJ, 471, 805
 Kirchner HH, 615
 Kirkwood JM, 195
 Kirsch M, 541
 Kish J, 471
 Kishida T, 1575
 Klein JL, 289, 1981
 Klepp O, 1437
 Klock JC, 2085
 Knight WA, III, 2099
 Knospe WH, 1495
 Knost JA, 1729
 Kochwa S, 475
 Koeller JM, 1215
 Kohler M, 1235
 Koretz MM, 1475, 1885

Kosloff C, 247
 Kosunoki T, 1575
 Kovach JS, 283, 1579
 Koziner B, 907
 Krakoff IH, 1321, 1327
 Kramer S, 805
 Kraut EH, 1673
 Kreja L, 1949
 Krivit W, 399, 1583
 Kroener JF, 1133
 Krook JE, 2093
 Kuenzlen E, 1723
 Kufe DW, 299
 Kuhn JG, 1869
 Kukla LJ, 369
 Kun L, 1791
 Kung F, 937
 Kuraishi Y, 1645
 Kyle RA, 451

L

Lad T, 369
 Lagarde C, 1563
 Lakey WH, 1837
 Landaw SA, 1495
 Lane WW, 197
 Lange B, 1699
 Langston CM, 1881
 Lanzotti VJ, 375
 Laroche D, 1759
 Larson DF, 259
 Larson RA, 767
 Lasnitzki I, 1375
 Lassiani L, 1751, 1945
 Laster WR Jr, 1187
 Laszlo J, 1495
 Lavin PT, 1567
 Lawrence HJ, 1475
 Lawrence J, 1885
 Lawrence R, 871
 Layton DD, Jr, 1647
 Lazarus P, 1595
 Lea JW, Jr, 1399
 Leavitt J, 1409
 Leclair R, 1759
 Lee BJ, 907
 Lee CKK, 819
 Lee KL, 1077
 Lee YJ, 31
 Legha S, 385, 1651, 1991
 Lehar TJ, 1399
 Lehotay DC, 311
 Leichman CG, 1447
 Leichman L, 203, 549, 2099
 Leichner PK, 289
 Leith JT, 1545
 LeRoy AF, 1529
 Lessner LE, 1439

Lester R, 2027
 Le Talaer JY, 1909
 Leventhal BG, 2013
 Levey BA, 311
 Levey GS, 311
 Levi F, 1933
 Levi JA, 177, 1242
 Levi-Schaffer F, 107
 Levin J, 1449
 Levine AS, 1391, 1699
 Levine NS, 1315
 Levitt M, 1237, 1553
 Levitt SH, 819
 Lewis JP, 1475
 Lien HH, 1219
 Lin CM, 1381
 Lippman ME, 1229
 Lipton A, 1303
 Lister TA, 377, 759
 Litterst CL, 147, 157, 1661
 Lloyd HH, 183
 Loesch DM, 2099
 Logothetis CJ, 57, 1501
 Loh J, 471
 Lokich JJ, 1713
 Longo DL, 925, 1975
 Loo TL, 85, 1631
 Looney WB, 1521
 Loutfi A, 409
 Low JE, 1889
 Lowe MC, 157, 1571
 Lowenthal RM, 505
 Luedke DW, 1409
 Luedke SL, 1409
 Luna MA, 2033
 Lurie P, 1273

M

Macbeth FR, 1719
 Macdonald JS, 1
 Machover D, 1803
 MacKay IS, 1884
 Madajewicz S, 197
 Mador D, 1837
 Magri MD, 559, 1207, 1877
 Mahal PS, 1613
 Maizel AL, 633
 Makuch RW, 217, 1743
 Malone JM, 259
 Maloney TR, 1257
 Malpas JS, 377, 759
 Mandel EM, 1291
 Manegold C, 1785
 Mangiacasale D, 483
 Mangioni C, 231, 1233
 Maral R, 1803
 March P, 915
 Marcus F, 1235

Margolese R, 1595
 Marit G, 2107
 Markman M, 1880
 Marks V, 1365
 Marraro D, 1819
 Marsh JC, 499
 Martini N, 1405
 Martoni A, 1763, 1819
 Mason BA, 243, 1609
 Mass R, 1587
 Massa G, 2061
 Mathé G, 1529, 1803
 Mattox D, 2097
 Mauch P, 733, 809, 1015
 Mayer RJ, 1455
 McCarthy LE, 363, 1625
 McClure P, 949
 McCormack JJ, 1321, 1327
 McCormack K, 2027
 McCracken JD, 31, 549, 1779
 McCredie KB, 1991
 McCullough DC, 2013
 McDonald B, 371, 1779
 McDonald RN, 1403
 McGovren JP, 1333
 McGuire WP, 369
 McGunagle D, 147
 McIntyre OR, 451, 475
 McKee MJ, 1845
 McKinney DR, 583
 McManus ME, 1343
 McPhee MS, 1837
 McPherson HL Jr, 91
 Mead GM, 1719
 Medina W, 195
 Meeker B, 1837
 Meguro S, 1645
 Mehta S, 633
 Mellstedt H, 701
 Mendelsohn J, 1399
 Merlano M, 585
 Merluzzi VJ, 535
 Merrill JM, 2021
 Meshad MW, 299
 Meshorer A, 107
 Messerschmidt G, 2027
 Metzgar RS, 667
 Meyskens FL, 593, 1315
 Micetich KC, 1813
 Michaelson R, 1757
 Michalski B, 1803
 Mietlowski WL, 1273
 Mikouchi S, 1645
 Miliauskas JR, 653
 Miller CF, 1678
 Miller DR, 483
 Miller HJ, 1244
 Miller TP, 553, 645
 Minna JD, 1223
 Minnhaa G, 385
 Minton MJ, 1445
 Mira J, 1113

Misset JL, 1803
 Mitchell EP, 1995
 Mittelman A, 81
 Moayeri H, 43
 Moccio DM, 351
 Moertel CG, 77, 1567
 Moore R, 1837
 Morag B, 2000
 Morantz EA, 575
 Morrison A, 410, 1211
 Morrison FS, 1257
 Mouridsen HT, 2081
 Mughal T, 1884
 Muhs WH, 317
 Muir W, 211
 Murphy S, 1495
 Murray K, 1549
 Muss H, 1775
 Muzzulini C, 2061
 Myers J, 907
 Myers JW, 1869

N

Naeher C, 43
 Nasca S, 2039
 Natale RB, 208, 2091
 Nawabi IU, 451
 Neefe J, 1995
 Neely SM, 827
 Neijstrom E, 541
 Neiman RS, 855, 2021
 Nelson JC, 25
 Nerenberg MI, 1279
 Nettesheim KM, 1601
 New JS, 91
 Newcome SR, 751
 Newcomer LN, 1279
 Newman RA, 1321
 Ng RP, 1977
 Nichol CA, 99
 Nichols WC, 1665
 Nicolau G, 1173
 Nines R, 1635
 Nirenberg A, 1687
 Nisce LZ, 907
 Nisi C, 115, 1751
 Nissen NI, 799, 835, 889, 1035
 Noble JF, 1139, 1145
 Nordentoft AM, 799
 Nordlund M, 871
 North L, 789

O

O'Bryan RM, 1113, 1651, 2099
 O'Connell MJ, 77, 2021
 O'Donnell JF, 410

Occhipinti SJ, 1159
 Ochoa M Jr, 1591
 Oechler H, 1791
 Ogenstad S, 701
 Ohnuma T, 65, 1509
 Oishi N, 31, 549, 1593
 Oku T, 1575
 Olah E, 343, 2071
 Olson M, 549
 Omura GA, 591
 Order SE, 289, 1981
 Orlow EL, 855
 Osborne L, 2027
 Østerlind K, 305
 Ostrowski MJ, 1903
 Ovejera A, 1635
 Ozols RF, 1767

P

Paccagnella A, 1247
 Padilla F, 31
 Pagano M, 1285
 Page J, 1242
 Pajak TF, 451, 475, 835, 889, 1035
 Panasci LC, 1595
 Pannacciulli I, 2061
 Pannuti F, 1763, 1819, 2043
 Papandopoulous N, 529
 Pardi G, 1681
 Park CH, 1257
 Parker M, 2027
 Parker MK, 289
 Parrilli G, 1435
 Pasmantier M, 1675
 Passe S, 907
 Paul AR, 557
 Pavkov KL, 1939
 Pavlovsky S, 1596
 Pavy MD, 457
 Pederson AG, 273, 407
 Pegelow CH, 2085
 Pelsor FR, 1223
 Pendergrass KB, 1880
 Pendyala L, 509
 Perloff M, 1875
 Peroutka SJ, 1449
 Perrault D, 717, 1783
 Perry DJ, 592
 Perry M, 1667, 1875
 Perry MC, 410, 1997
 Peterson BA, 563, 889
 Peterson DE, 1251
 Petruska P, 237, 1409
 Pfeifle C, 1723
 Phillips RH, 1884
 Phillips T, 2027
 Piana E, 1763
 Picci P, 1859
 Pignon B, 1983

Pinkel D, 1791
 Pino y Torres J, 1981
 Pisciotto AV, 1495
 Plager J, 43
 Platina O, 205
 Pleasants ME, 1933
 Plouvier E, 1983
 Pocelinko R, 1517, 1869
 Poplack DG, 387, 1333
 Poplin EA, 1557
 Portlock CS, 417
 Poulin RF, 1211
 Powell DM, 157
 Powers JF, 1889
 Powis G, 77, 283
 Preisler HD, 1073, 1463
 Presant CA, 199, 1431
 Priester ER, 517
 Priore RL, 81
 Prosnitz LR, 855, 871, 1279
 Pugh R, 31

Q

Qazi R, 405
 Quirt I, 1783

R

Rabadi SJ, 1244
 Rafla S, 835
 Raich PC, 1729
 Rajdev N, 1678
 Rankin E, 1771
 Ratanatharathorn V, 1231, 1587
 Ratner LH, 1509
 Raza A, 1073
 Raza S, 197
 Reddel RR, 19
 Reed G, 1409
 Reed R, 1113
 Reimer RR, 1680
 Reisman A, 1291
 Rentschler RE, 25, 1399
 Resser KJ, 1235
 Reusch K, 391
 Reynolds RD, 1475, 1885
 Ribaud P, 1529
 Ricci JA, 410
 Richards FI, II, 1211, 1997
 Richter MP, 1609
 Rick AC, 91
 Rideout DF, 717
 Rider WD, 489
 Ries CA, 1475
 Ritch PS, 1159
 Ritchie B, 1837
 Ritter S, 205

Rivkin SE, 1587, 1869
 Roberts BJ, 1187
 Roberts J, 1479
 Robins MJ, 317
 Rogers JS II, 1729
 Rogerson BJ, 311
 Rojev R, 1299
 Roncadin M, 559, 1207
 Ronen M, 2000
 Rørth M, 305
 Rose WC, 135, 1831
 Rosen G, 1687
 Rosen N, 1449
 Rosenberg SA, 743
 Rosenbloom BE, 594
 Rosenblum MG, 1631
 Rosenfelt FP, 594
 Rosenschein NB, 1981
 Rosenthal CJ, 205
 Rosenthal DS, 733, 1015, 1455, 1495
 Roskos RR, 961
 Ross D, 1957
 Ross WE, 359
 Rossi A, 403
 Rossi C, 121
 Rosso R, 585
 Roth HB, 259
 Rowley JD, 639
 Royston I, 1399
 Rozenbaum A, 1983
 Rubens RD, 1445
 Rubin J, 77
 Rudders RA, 1785
 Rudnick SA, 541
 Rustgi VK, 2095
 Rustum YM, 81

S

Saesow N, 1365
 Sakers JH, 583
 Saiki J, 1651, 1673
 St-Germain J, 1595
 Salazar O, 1417
 Saleh F, 1133
 Salles B, 327
 Salmon SE, 1267, 1315
 Saltiel M, 369
 Salvagno L, 1247
 Samson MK, 371, 1113, 1447
 Samuels ML, 57, 1501
 Sandison AG, 1605
 Santoro A, 881
 Sarna GP, 277
 Sather H, 399
 Saunders F, 949
 Sava G, 115, 179, 1751
 Sawada T, 1575
 Scaglione C, 1596
 Scarffe H, 1997

Schaadt M, 615
 Schabel FM, Jr, 1187
 Schackney SE, 1159
 Schacter B, 1553
 Schaff BF, 2027
 Schein P, 1667
 Schein PS, 1563, 1995, 2095
 Schell FC, 1641
 Scher H, 1653
 Schertz G, 2095
 Schiffer CA, 267
 Schilling A, 410, 1273
 Schilsky RL, 1767
 Schipper H, 1237, 1553
 Schmähl D, 391
 Schneider RJ, 1591
 Schulman P, 171, 173, 1675
 Schurig JE, 135, 187, 1831
 Schutt AJ, 567, 1239, 1425, 2089
 Schwade JB, 1743
 Schwartz S, 1653
 Schwartzberg L, 1803
 Schweitzer J, 1303
 Scott M, 1647, 2093
 Seagren SL, 1399
 Seematter RJ, 1307
 Seidel HJ, 1949
 Selner M, 317
 Seltzer V, 1809
 Sellwood RA, 1997
 Semprini AE, 1681
 Senapati N, 1635
 Serano RD, 99
 Sessa C, 231, 1233, 1681
 Seydel HG, 1113
 Shah KA, 1449
 Shah MK, 557
 Shand WS, 759
 Sharp TR, 571
 Sheehan W, 937
 Shimoaka K, 43
 Shinder M, 1595
 Shoemaker DD, 1343
 Shullenberger CC, 789
 Shulman HM, 1863
 Siaw MFE, 253
 Sieber SM, 517
 Siegel SE, 2105
 Sigel CW, 99
 Siggurdsson K, 1441
 Sikic BI, 147
 Sileni VC, 1247
 Silver BA, 1229
 Silverman M, 1439
 Silverstein ME, 751
 Simon R, 31, 1083
 Simonsen E, 1441
 Singleton RT, 1003
 Sinks LF, 2013
 Sinoff C, 1605
 Sirotak FM, 351
 Skalski V, 1595

Skibba JL, 1365
 Skramstad K, 1159
 Slack JA, 1957
 Sladek NE, 1889
 Slavik M, 583, 1775
 Slawson RG, 711, 1003
 Slayton RE, 1669
 Slymen DJ, 1917
 Smith BJ, 1884
 Smith FP, 1563, 1661, 1995, 2095
 Smith L, 1995
 Smith PC, 1889
 Smith RB, 1333
 Smyth JF, 463
 Soares N, 1333
 Sobrero A, 2061
 Solomon JK, 81
 Somers R, 1967
 Sonis ST, 1251
 Sonley M, 949
 Sörenson S, 273
 Sorrenti V, 1421
 Souhami RL, 463
 Sparano BM, 1145
 Spicer KM, 1003
 Spiro SG, 463
 Spitzer G, 385, 1991
 Sridhar KS, 1509
 Stablein DM, 1713
 Stanley K, 1417
 Stansfeld AG, 759
 Stanton W, 1399
 Starmer CF, 1077
 Stein H, 615
 Stein RS, 733, 1107
 Steiner LJ, 483
 Steiner PG, 483
 Steinhorn SC, 653
 Stephens RL, 1673, 1781
 Stevens EE, 2005
 Stewart D, 73
 Stewart JA, 1327
 Stewart JC, 1333
 Stewart JF, 1445
 Stoopler M, 247
 Stragand JJ, 529
 Straus DJ, 907, 1121
 Straus MJ, 1797
 Strocchi E, 1819, 2043
 Stroehlein JR, 1613
 Strong JM, 1343, 1743
 Stuckey WJ, 1113
 Stutzman L, 43, 835, 1035
 Subramanian VP, 1729
 Sueno K, 615
 Sullivan JA, 789
 Sullivan MP, 937
 Surwit EA, 1315
 Susskind BM, 535
 Sutcliffe SB, 759
 Sutherland CM, 409
 Sweet DL, 1107

T

Taetle R, 1399
 Talamini R, 1882
 Talley RW, 371, 1231, 1779
 Talpaz M, 587
 Tamassia V, 1819
 Tan CTC, 483, 969
 Tan TH, 317
 Tanaka T, 1575
 Tannock I, 1421, 1783
 Tartaglia AP, 1495
 Tashkin DP, 589
 Tattersall MHN, 19, 177, 1242
 Taylor HG, 592
 Taylor SG, IV, 1594
 Tefft M, 937
 Telhaug R, 1437
 Teres D, 1371
 Ternberg J, 937
 Thake DC, 1939
 Thant M, 2097
 Thatcher N, 1771
 Thomas ED, 1463
 Thomas GM, 489
 Thomas LT, 1967
 Thompson G, 1549
 Thompson T, 1867
 Thrall JH, 493
 Threadgill MD, 1957
 Tieche M, 1561
 Tillery KF, 183
 Tilley LP, 1139
 Timothy AR, 759
 Tirelli U, 167, 559, 1207, 1877, 1882, 1971
 Todd D, 1977
 Todd RF, III, 1585
 Toledo CH, 359
 Torres LJ, 147
 Torti FM, 1475, 1885
 Tourani JM, 1803
 Tozawa M, 1575
 Trader MW, 1187
 Trindade A, 57, 1501
 Trivedi SM, 1535
 Tropé C, 1441
 Trouet A, 395
 Trovò MG, 167, 559, 1207, 1877, 1882, 1971
 Trueworthy RC, 1881
 Trump DL, 1549
 Tumolo S, 167, 559, 1207, 1877, 1882, 1971
 Tunca JC, 1285
 Turbow MM, 163
 Tyson LB, 2108

U

Uchanska-Ziegler B, 615
 Ultmann JE, 733, 767, 1107
 Ungerleider JT, 589

Unwin SE, 1845
Uphouse WJ, 1593
Urbanek MA, 1845

V

Vaglini M, 1299
Vaidya AB, 1169
Valagussa P, 881
Valdivieso M, 73, 1641
Valente I, 1233
Van Amburg AL III, 1431
Van Echo DA, 221, 1127, 1237, 1557, 1773, 1869, 2097
Vats TS, 575, 1881
Vaughn C, 381
Vaughn CB, 1591
Velasquez WS, 789
Vellekoop L, 385, 1991
Verma DS, 385, 1991
Veronesi A, 167, 559, 1207, 1877, 1882, 1971
Villar HV, 751
Villar J, 1981
Vincent RG, 197
Vinciguerra V, 171, 173, 835, 1675
Vogel CL, 1867
Vogel SE, 1285, 1417
Vogelzang N, 410, 1683
Vogl SE, 1809
von Eschenbach AC, 57
Von Hoff DD, 1333, 1779, 1869, 2097
Vosika G, 410
Vugrin D, 1405

W

Wagstaff J, 1771
Walker BK, 1729
Wallace S, 1501
Warnke R, 609
Warrell RP Jr, 1121, 1479, 1619
Wasserman LR, 1495
Watson RC, 208, 1653, 2091
Weatherall T, 1113
Weaver A, 471
Weber G, 343, 2071
Wedelin C, 701
Weick JK, 553
Weinberg V, 1211, 1667, 1875
Weinerman B, 1553
Weinfeld A, 1495
Weinstein HJ, 1455
Weinstein IM, 594
Weiselberg L, 171, 1675
Weiss GB, 545
Weiss GR, 299
Weiss RB, 427, 592, 1997
Wells J, 277
Wesley MN, 1003, 1975

Wharam M, 937
Wharam M, 289, 1549, 2013
Wheeler RH, 493
Whitacre M, 221, 1127, 1557
Whitby H, 1957
White DS, 1303
White JE, 1113
White RA, 529
Whitehouse JM, 1719
Whitmore WF Jr, 5, 1405
Wick MM, 1657
Wiernik PH, 221, 267, 711, 733, 1003, 1127, 1237, 1557, 1773, 2097
Wik B, 1219
Wilbur DW, 25
Wilbur JR, 2085
Wilcox JH, 1601
Wiley EL, 457
Williams CJ, 1719
Williams SD, 15, 1709, 2005
Wilson HE, 1587
Windschitl HE, 2093
Woo SY, 2013
Wood JH, 1333
Wood T, 1397
Wood W, 1211, 1667, 1875
Woodcock TM, 1591
Woods RL, 177
Woolley PV, 1596, 1901, 1995, 2095
Wortmann RL, 387
Wrigley PFM, 759
Wu WH, 1173
Wynert WR, 1303

Y

Yagoda A, 208, 1653, 2091
Yancey RS, 587
Yap B-S, 1517
Yap H-Y, 1517, 1641
Yoda T, 1645
Young AB, 211
Young CW, 907, 1121, 1479, 1619, 1757
Young JA, 1399
Young RC, 653, 925, 1813, 1975

Z

Zagonel V, 1274
Zander AR, 385, 1991
Zbinden G, 1677
Zelen M, 1095
Zeller WJ, 391
Ziegler A, 615
Zukoski CF, 259
Zumoff B, 1449
Zwelling LA, 1813

Reviewers

We wish to thank the following Reviewers who participated in evaluating the manuscripts submitted to *Cancer Treatment Reports* during the past year:

Betty Jane Abbott
Ross A. Abrams
David L. Ahmann
David S. Alberts
Raymond Alexanian
Joseph C. Allegra
Muhyi Al-Sarraf
Carl Alving
Matthew M. Ames
Tom Anderson
Frederick R. Appelbaum
Marc M. Applefeld
Bach Ardalan
Zalman Arlin
James O. Armitage
James Arseneau
Nicholas Bachur
Laurence H. Baker
Judith L. Bader
Sam C. Barranco
Robert C. Bast
Gerald Batist
Stephen Baylin
Lewis Becker
Robert J. Belt
Richard A. Bender
Robert S. Benjamin
John M. Bennett
John A. Benvenuto
Jeffrey Berenberg
Daniel E. Bergsagel
Bijoy K. Bhuyan
Ilan Bikel
Jacob D. Bitran
Werner A. Bleyer
Ronald H. Blum
George K. Blumenschein
Gerald P. Bodey, Jr
Arthur E. Bogden
Herbert L. Borison
Leslie E. Botnick
Donnell Bowen
Ed Bradley
David Braun, Jr
Dean Brenner
Harmar D. Brereton
R. Wallace Brockman
Lawrence E. Broder
Samuel Broder
Richard H. Bromer

Arthur Brown
W. R. Bruce
Howard W. Bruckner
Salvador Bruno
Daniel R. Budman
Paul A. Bunn, Jr
Raymond S. Bush
Aman Buzdar
David P. Byar
Patrick Byrne
Fernando Cabanillas
Ed Cadman
George P. Canellos
E. S. Cannellakis
Robert Capizzi
Desmond N. Carney
Walter H. Carter, Jr
Delvyn Case, Jr
Ephraim S. Casper
A. Philippe Chahinian
Yung Chi Cheng
Paul A. Chervenick
Robert Chilcote
Michael A. Chirigos
Delia F. Chiuten
Rowan T. Chlebowski
William Clark
Jacob J. Clement
Carmel J. Cohen
Martin H. Cohen
Philip Cohen
Samuel M. Cohen
Morton Coleman
C. Norman Coleman
Charles A. Coltman, Jr
Michael Colvin
Steven Come
Robert L. Comis
James R. Commers
Peter Conroy
David A. Cooney
M. Robert Cooper
Thomas H. Corbet
Brian Corden
Mary E. Costanza
John J. Costanzi
Kenneth Cowan
James D. Cox
Edward T. Creagan
Richard H. Creech

William Crist
 Steven Culbert
 Gregory Curt
 Richard Cysyk
 James M. Dambrosia
 Giulio J. D'Angio
 John R. Daniels
 J. Paul Davignon
 Hugh L. Davis
 Thomas E. Davis
 Robert L. Dedrick
 Dennis Deen
 Manu H. Desai
 William Dewey
 William D. DeWys
 Robert B. Diasio
 Philip J. Disaia
 Sara S. Donaldson
 Michele G. Donehower
 Ross C. Donehower
 Agnes Donohue
 James H. Doroshow
 Robert T. Dorr
 Evan Douple
 Lois W. Dow
 John R. Durant
 Brian G. M. Durie
 Frederick E. Durr
 Janice P. Dutcher
 Robert T. Eagan
 Robert H. Earhart
 Joseph Eggleston
 Merrill J. Egorin
 Lawrence H. Einhorn
 Gertrude B. Elion
 Rose Ruth Ellison
 Paul F. Engstrom
 William Ensminger
 Leonard Erickson
 Charles Erlichman
 Thomas Ervin
 David S. Ettinger
 Audrey E. Evans
 Ronald Feld
 Joseph D. Fenstermacher
 Isaiah J. Fidler
 Richard I. Fisher
 Joseph Fontana
 K. Foon
 Arlene Forastiere
 Clarence L. Fortner
 Christopher Frantz
 Emil Frei, III
 Emil J. Freireich
 Arnold Fridland
 Howard Friedman
 Michael A. Friedman
 Stephen Frytak
 Ruth A. Fugmann
 Joachim Z. Fuks
 Betty E. Furnas

John Jacob Furth
 June E. Fusner
 Glen R. Gale
 Robert Peter Gale
 Robert E. Gallagher
 Joseph E. Gallelli
 Richard A. Gams
 Marc B. Garnick
 Adi Gazdar
 Edward Gelman
 Steven George
 Ruth I. Geran
 Teresa Gessner
 Harriet S. Gilbert
 James R. Gillette
 Sandra J. Ginsberg
 Eli Glatstein
 Daniel L. Glaubiger
 Robert I. Glazer
 John Glick
 Robert B. Golbey
 Abraham Goldin
 I. David Goldman
 Harvey M. Golomb
 German A. Gomez
 Bruce Gordon
 Paul Gormley
 John S. Gottdiener
 Theodor B. Grage
 Richard J. Gralla
 Michael Graham
 Richard J. Gralla
 F. Anthony Greco
 Daniel M. Green
 Mark R. Green
 Bernard R. Greenberg
 Gerald B. Grindey
 Daniel P. Griswold, Jr
 Louise B. Grochow
 Stuart Grossman
 Leonard L. Gunderson
 Philip Gutin
 John W. Gyves
 Charles D. Haas
 Mutoz Habel
 George M. Hahn
 Daniel G. Haller
 Anne Hamberger
 Ernest Hamel
 Bruce Hamilton
 Tin Han
 Kenneth Hande
 Heine H. Hansen
 Harold C. Harder
 K. R. Harrap
 Harold Harvey
 Frances A. Hayes
 Edward S. Henderson
 I. Craig Henderson
 Eugene H. Herman
 Evan Hersh

Roger H. Herzig
 Donald J. Higby
 Donald L. Hill
 Clark H. Hoagland
 Freddie A. Hoffman
 Philip Hoffman
 John S. Holcenberg
 Jimmie Holland
 Paul Y. Holoye
 Jordan L. Holtzman
 Gabriel N. Hortobagyi
 John Horton
 David P. Houchens
 Janet Houghton
 Peter Houghton
 Mark Huberman
 Frank Iber
 Daniel C. Ihde
 James N. Ingle
 Mark Israel
 Brian F. Issell
 Don V. Jackson
 Robert Jackson
 Charlotte Jacobs
 Roger S. Jaenke
 Norman Jaffe
 Nasser Javadpour
 David W. Jayme
 Randall K. Johnson
 Jacques Jolivet
 Roy B. Jones
 Stephen E. Jones
 Barry H. Kaplan
 Richard S. Kaplan
 Michael J. Keating
 David Kelsen
 B. J. Kennedy
 David H. Kern
 Ian Kerr
 David T. Kiang
 Merrill Kies
 John G. Killen, Jr
 Bruce F. Kimler
 Charles M. King
 Timothy Kinsella
 Daniel Kisner
 Curtis D. Klaassen
 Leonard Klein
 Philip Klubes
 William A. Knight, III
 Paul L. Kornblith
 John S. Kovach
 Irwin H. Krakoff
 Margaret Kripke
 Thomas Kubota
 Donald W. Kufe
 John G. Kuhn
 Robert A. Kyle
 Thomas E. Lad
 John Laszlo
 John Lazo

Richard D. Leavitt
 Insu Lee
 Sewa S. Legha
 Steven A. Leibel
 Larry Leichman
 Raymond E. Lenhard, Jr
 W. R. Leopold, III
 André F. LeRoy
 Howard Lessner
 Brigid G. Leventhal
 Bernard Levin
 Victor A. Levin
 Arthur S. Levine
 Richard Levine
 Brian J. Lewis
 Brian Leyland-Jones
 Alan Lichter
 Michael Lieber
 Victor Ling
 Marc E. Lippman
 Allan Lipton
 Robert H. Liss
 Charles L. Litterst
 Robert B. Livingston
 Harris H. Lloyd
 Christopher Logethetis
 Jacob J. Lokich
 Dan L. Longo
 Ti Li Loo
 Michael C. Lowe
 David B. Ludlum
 Susan Luedke
 John S. Macdonald
 Gordon B. Magill
 Richard L. Magin
 Ian I. Magrath
 M. Stephen Mahaley, Jr
 Robert W. Makuch
 Louis Malspeis
 Gilbert J. Mannering
 Michael R. Manning
 Bernie Mansheim
 Richard Margolese
 Sanford Markey
 Jane B. Marmor
 Silvia Marsoni
 Daniel S. Martin
 Alvaro Martinez
 Michael Mastrangelo
 Mary J. Matthews
 Harold Maurer
 Robert J. Mayer
 Kenneth B. McCredie
 William P. McGuire, III
 O. Ross McIntyre
 Gerald Medoff
 James Meek
 Monte Melzer
 Frank Meyskens, Jr
 Kenneth Micetich
 Bruce A. Mico

Thomas Miller
 Jon Minford
 James Miser
 Edith P. Mitchell
 James Mitchell
 Charles G. Moertel
 F. K. Mostofi
 Franco M. Muggia
 Charles E. Myers
 Ronald B. Natale
 Larry Nathanson
 John Neefe
 James A. Neidhart
 Robert L. Nelson
 Mark E. Nesbit
 Norman D. Nigro
 Larry Norton
 Michael J. O'Connell
 Takao Ohnuma
 James Okunewick
 Robert K. Oldham
 Stanley E. Order
 C. Kent Osborne
 Artemio A. Ovejera
 Robert F. Ozols
 Demetrios Papahadjopoulos
 Joseph Parrillo
 Alan Pastronk
 A. R. P. Paterson
 David F. Paulson
 Gary L. Peck
 Lakshmi Pendyala
 John S. Penta
 Carlos A. Perez
 Elliott Perlin
 Marjorie Perloff
 Michael C. Perry
 Bruce A. Peterson
 Frederick S. Philips
 David A. Pistenmaa
 M. Steven Piver
 Philip A. Pizzo
 William Plunkett
 Jeffrey J. Pollen
 David G. Poplock
 Carol D. Portlock
 Juan G. Posada
 Donald S. Poster
 Hipolito Poussin
 Garth Powis
 Harvey D. Preisler
 Thongbliew Prempree
 Gary A. Present
 Archie W. Prestayko
 David J. Prieur
 Charles Pruet
 Peter Quesenberry
 Kanti R. Rai
 Herbert J. Rapp
 Mario J. R. Ravry
 Gregory H. Reaman

Steven D. Reich
 Ralph D. Reynolds
 D. S. Rigel
 Charles E. Riggs, Jr
 Paul S. Ritch
 Gaston Rivera
 Kay Robichaud
 William A. Robinson
 William C. Rose
 Steven D. Rosen
 Neil Rosenshein
 Fred Rosner
 Norma Rubin
 Alfred R. Rudolph
 Diane H. Russell
 Angelo Russo
 Yousef Rustum
 Fred Ruyman
 Omar M. Salazar
 Stephen Sallan
 Michael K. Samson
 David R. Sanderson
 Richard J. Santen
 George W. Santos
 Gregory Sarna
 Alan C. Sartorelli
 Philip S. Schein
 Lewis M. Schiffer
 Richard L. Schilsky
 Stephen C. Schimpff
 Joe Schulman
 Philip Schulman
 J. E. Schurig
 V. Sagar Sethi
 William R. Shapiro
 Alan Shefner
 Richard J. Sherins
 Stephen A. Sherwin
 Robert Shoemaker
 George Siber
 Susan M. Sieber
 Stuart E. Siegel
 Branimir Ivan Sikic
 Richard T. Silver
 Richard M. Simon
 Linda Simpson-Herren
 Lucius F. Sinks
 Francis M. Sirotnak
 Arthur T. Skarin
 Howard Skipper
 Richard V. Smalley
 Frederick P. Smith
 Michael Smolensky
 Benjamin Sparano
 James L. Speyer
 Robert J. Spiegel
 Alexander S. D. Spiers
 Gary Spitzer
 Michael B. Sporn
 Ellen Spremulli
 Ronald Stephens

J. Robert Stewart
 Patricia Stewart
 Joan Stratton
 David J. Straus
 James A. Straw
 Thomas A. Strike
 James E. Strong
 John M. Strong
 Matthew Suffness
 Paul Sugarbaker
 Robert Sutherland
 Raymond Taetle
 Charlotte T. Tan
 Joel Tepper
 J. Tate Thigpen
 Snorri S. Thorgeirsson
 Frank M. Torti
 Thomas N. Tozer
 Frank Traganos
 Mary W. Trader
 Elizabeth L. Travis
 V. K. Vaitkevicius
 Manuel Valdivieso
 David Van Echo
 Kerry Van Sloten
 Gary Van Zant
 David T. Vistica
 Charles L. Vogel
 Nicholas J. Vogelzang
 Steven E. Vogl
 W. R. Vogler
 Daniel Von Hoff
 Davor Vugrin
 James Wade
 Michael D. Walker

Galen L. Wampler
 Yeu-Ming Wang
 Raymond P. Warrell, Jr
 Todd Wasserman
 Roy Weiner
 Howard J. Weinstein
 Larry M. Weisenthal
 A. F. Weiss
 Raymond B. Weiss
 James C. Wernz
 Jacqueline Whang-Peng
 Max Wicha
 Michael M. Wick
 Peter H. Wiernik
 Patti M. Wilcox
 Lee J. Wilkoff
 James A. Will
 Stephen D. Williams
 James K. V. Willson
 Robert E. Wittes
 Isidore Wodinsky
 William C. Wood
 Thomas Woodcock
 Kay H. Woodruff
 Alan Yagoda
 Hwee-Yong Yap
 Charles W. Young
 David M. Young
 Robert C. Young
 Daniel S. Zaharko
 Berton Zbar
 Gerhard Zbinden
 Solomon Zimm
 Leonard A. Zwelling